

JOHN H. ALEXANDER, M.D., M.H.Sc.

DUKE UNIVERSITY MEDICAL CENTER  
CURRICULUM VITAE

Date Prepared: January 1, 2019

**Name:** John Hunter Peel Alexander, M.D., M.H.Sc.

**Address:** Box 3300  
Duke University Medical Center  
Durham, NC 27710-7510  
Phone: (919) 668-8955, Fax: (919) 668-7085  
Email: John.H.Alexander@duke.edu

**Primary academic appointment:** Department of Medicine, Division of Cardiology

**Present academic rank and title:** Professor of Medicine w/ Tenure April 2014-present

**Date and rank of first Duke faculty appointment:** July 1, 2000, Assistant Professor of Medicine

**Medical licensure:** North Carolina License #NC-9600017

**Date of license:** June 30, 1996

**Specialty certification(s) and dates:**

Internal Medicine (#166933) 08/21/1996, valid through 12/31/2016  
Cardiovascular Diseases (#166933) 11/08/2000, valid through 12/31/2020 Echocardiography  
(#052150) 12/02/2005, valid through 06/30/2026  
ACSL/BLS/AHA (#NC 05353) Valid through 10/2019

**Date of birth:** July 5, 1966 **Place:** Pittsburgh, PA, USA

**Citizen of:** United States of America

<b>Education:</b>	<u>Institution</u>	<u>Date</u>	<u>Degree</u>
High School:	Allderdice High School, Pittsburgh, PA	1984	Diploma
College	Oberlin College, Oberlin, OH	1989	B.A. w/High Honors
Medical School	Univ of Pennsylvania, Philadelphia, PA	1993	M.D.
CRTP	Duke University, Durham, NC	2001	M.H.Sc.

**Scholarly societies:** (Alpha Omega Alpha, Sigma Xi, Phi Beta Kappa; etc):

Phi Beta Kappa 1989  
Sigma Psi, Scientific Research Society 1989

Alpha Omega Alpha, Medical Honor Society	1993
American Society of Clinical Investigation	2015

**Professional training and academic career:**

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
Brigham and Women's Hospital, Boston, MA	Medicine Intern	1993–1994
Brigham and Women's Hospital, Boston, MA	Medicine Resident	1994–1996
Duke University Medical Center, Durham, NC	Cardiology Fellowship	1996–2000
Duke Clinical Research Institute, Durham, NC <i>Clinical Research Projects: GUSTO-IIIb, PARAGON-A, PARADIGM, APLAUD, ASSENT-2, LEAP, ASSENT-3</i>	Research Fellow	1996–2001
Duke University School of Medicine, Durham, NC	Assistant Professor	2000–2007
	Associate Professor	2007–2010
	w/ Tenure	2010–2014
	Professor	2014–present
Vice Chief for Clinical Research – Cardiology		2012–present
Duke Clinical Research Institute, Durham, NC	Research Faculty	2000–present
Early Phase Cardiovascular Research	Director	2005–2010
Cardiovascular Research	Co-Director	2010–2012
Cardiovascular Research	Director	2012–present
Faculty	Associate Director	2013–present

*Clinical Research Projects: ASSENT-3 (Co-I), LEAP (PI), XaNADU-PCI (Co-PI), XaNADU-ACS (PI), PREVENT-IV (PI), SYNERGY (CEC Faculty Leader), CEGS Grant (NIH, Consultant), OASIS-5 (Site PI), SHOCK-2 Pilot (Data Center PI, Site PI), KILO (PI, Sponsor), GENE-MAGIC (NIH, Co-I), MEND-CABG (Site PI), TRIUMPH (Co-I), REGADO-IA (Co-I), ENDEAVOR Japan (Co-I), SEPIA-PCI (Co-I, Encrypted Heparin Monitoring), SPIRIT Japan (Co-I), APPRAISE (PI), REGADO-1B (Co-I), MEND-CABG 2 (Co-I), ARISTOTLE (Co-I), NAPA-CS (PI), REVERSAL-PCI (Co-I), APPRAISE-2 (PI), CT Surgery Network Clinical Center (NIH, Duke Site Co-PI), RED-CABG (DSMB Chair), RADAR (PI, Steering Committee Chair), CSL Phase 2a (PI), MAPS (Co-I), REGULATE-PCI (Co-PI), SECURE-PCI (Executive Committee), CARMELINA (Steering Committee), HARMONEE (DSMC Member), AEGIS-I (Executive Committee), LEVO-CTS (Study Chair), AUGUSTUS (Study Chair), MINT (Executive Committee), AEGIS-II (Executive Committee), ROMA (Steering Committee), TRAVERSE (DMC Chair), Zafgen Phase 2 (DMC Chair), BEAT-HF (Study Chair), QUORUM (Steering Committee)*

Duke University, Center for the Study of Medical Ethics and the Humanities	Faculty Associate	2001–2010
--	-------------------	-----------

**Publications:**

**Refereed journals:** (Refereed journals are scientific publications that have active editorial boards and a system of critical review of all submissions for publication)

1. **Alexander JH**, Harrington RA. Antiplatelet and Antithrombin Therapies in the Acute Coronary Syndromes. *Curr Opin Cardiol* 1997;12:427-437 (PMID:9263656).
2. **Alexander JH**, Ohman EM, Harrington RA. Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Myocardial Infarction: Pathophysiology and Clinical Effects. *Acute Coronary Syndromes* 1998;1:46-51.
3. **Alexander JH**, Harrington RA. Recent Antiplatelet Drug Trials in the Acute Coronary Syndromes: Clinical Interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. *Drugs* 1998;56:965-976 (PMID:9878986).
4. **Alexander JH**, Granger CB, Sadowski ZP, Aylward PE, White HD, Thompson TD, Califf RM, Topol EJ; for the GUSTO-I and GUSTO-IIb Investigators. Prophylactic Lidocaine Use in Acute Myocardial Infarction: Incidence and Outcomes From Two International Trials. *J Am Heart Assoc* 1999;137:799-805 (PMID:10220627).
5. Sadowski ZP, **Alexander JH**, Skrabucha B, Dyduzynski A, Kuch J, Nartowicz E, Swiatecka G, Kong DF, Granger CB. Multicenter Randomized Trial of Lidocaine in Acute Myocardial Infarction and a Systematic Overview of Lidocaine in Acute Myocardial Infarction. *J Am Heart Assoc* 1999;137:792-798 (PMID:10220626).
6. **Alexander JH**, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt RM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW. Prior Aspirin Use Predicts Worse Outcomes in Patients with Non-ST-elevation Acute Coronary Syndromes. *Am J Cardiol* 1999;83:1147-1151 (PMID:10215274).
7. **Alexander JH**, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalan R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA; for the PURSUIT Steering Committee. Association Between Minor Elevations of Creatine Kinase-MB Level and Mortality in Patients with Acute Coronary Syndromes Without STsegment Elevation. *JAMA* 2000;283:347-353 (PMID:10647797).
8. Sparapani R, **Alexander JH**. Incorporating Quantitative Information into a Qualitative Composite Endpoint. *American Statistical Association, Proceedings of the Biopharmaceutical Sections* 2000:117-121.
9. Al-Khatib SM, Califf RM, Hasselblad V, **Alexander JH**, McCrory DC, Sugarman J. Placebocontrols in Short-term Clinical Trials of Hypertension. *Science* 2001;292:2013-2015 (PMID:11408643).
10. Angeja BG, **Alexander JH**, Chin R, Li X, Barron HV, Granger CB, Van de Werf F, Gibson CM. Safety of the Weight-adjusted Dosing Regimen of Tenecteplase in the ASSENT-2 Trial. *Am J Cardiol* 2001;88:1240-1245 (PMID:11728350).

11. Akkerhuis KM, **Alexander JH**, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML. Minor Myocardial Damage and Prognosis: Are Spontaneous and Percutaneous Coronary Intervention-related Events Different? *Circulation* 2002;105:554-556 (PMID:11827918).
12. Serebruany VL, Malinin AI, Callahan KP, Binbrek AS, Van de Werf F, **Alexander JH**, Granger CB, Gurbel PA. Effect of Tenecteplase Versus Alteplase on Platelets During the First Three Hours of Treatment for Acute Myocardial Infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) Platelet Substudy. *J Am Heart Assoc* 2003;145:636-642 (PMID:12679759).
13. **Alexander JH**, Harrington RA, Bhapkar M, Gardner L, Mahaffey KW, Lincoff AM, Ohman EM, Klootwijk P, Pahlm O, Henden B, Deckers JW, Simoons ML, Califf RM, Wagner GS. Prognostic Importance of New Small Q Waves Following Non-ST-elevation Acute Coronary Syndromes. *Am J Med* 2003;115:613-619 (PMID:14656613).
14. Sinnaeve PR, **Alexander JH**, Belmans A, Bogaerts K, Langer A, Diaz R, Ardellino D, Vahanian A, Armstrong P, Van de Werf P; for the ASSENT-2 Investigators. One-year Follow-up of the ASSENT-2 Trial: A Double-blind Randomized Comparison of Single-bolus Tenecteplase and Front-loaded Alteplase in 16,949 Patients with ST-elevation Acute Myocardial Infarction. *J Am Heart Assoc* 2003;146:27-32 (PMID:12851604).
15. Rebeiz AG, Roe MT, **Alexander JH**, Mahaffey KW, Granger CB, Peterson ED, Califf RM, Harrington RA. Integrating Antithrombin and Antiplatelet Therapies with Early Invasive Management for Non-ST-segment Elevation Acute Coronary Syndromes. *Am J Med* 2004;116:119-129 (PMID:14715326).
16. Roe MT, Mahaffey KW, Kilaru R, **Alexander JH**, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CB, Ohman EM, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Topol EJ. Creatinine Kinase-MB Elevation after Percutaneous Coronary Intervention Predicts Adverse Outcomes in Patients with Acute Coronary Syndromes. *Eur Heart J* 2004;25:313-321 (PMID:14984920).
17. **Alexander JH**, Peterson ED, Chen AY, Harding TM, Adams DB, Kisslo JA. Feasibility of Point-of-care Echocardiography by Internal Medicine House Staff. *J Am Heart Assoc* 2004;147:476-481 (PMID:14999197).
18. Waters RE, Singh KP, Roe MT, Mahaffey KW, Newby LK, **Alexander JH**, Harrington RA, Califf RM, Granger CB. Rationale and Strategies for Implementing Community-based Transfer Protocols for Primary Percutaneous Coronary Intervention for Acute ST-segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 2004;43:2153-2159 (PMID:15193673).
19. Sinnaeve P, **Alexander, JH**, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JAA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van de Werf FJ. Efficacy of Tenecteplase in Combination with Enoxaparin, Abciximab, or Unfractionated Heparin: Oneyear Follow-up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT3) Randomized Trial in Acute Myocardial Infarction. *J Am Heart Assoc* 2004;147:993-998 (PMID:15199346).
20. **Alexander JH**, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman L, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Saint-Jacques H, Chetcuti H, Burton JR, Buegler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW,

- Harrington RA; on behalf of the XaNADU-PCI PILOT Investigators. Initial Experience with Factor-Xa Inhibition in Percutaneous Coronary Intervention: the XaNADU-PCI Pilot. *J Thromb Haemost* 2004;2:234-241 (PMID:14995984).
21. Curtis JP, **Alexander JH**, Huang Y, Wallentin L, Verheugt FWA, Armstrong PW, Krumholz HM, Van de Werf F, Danays T, Cheeks M, Granger CB. Efficacy and Safety of Two Unfractionated Heparin Dosing Strategies with Tenecteplase in Acute Myocardial Infarction (Results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). *Am J Cardiol* 2004;94:279-283 (PMID:15276088).
  22. Weston P, **Alexander JH**, Patel MR, Maynard C, Crawford L, Wagner GS. Hand-held Echocardiographic Examination of Patients with Symptoms of Acute Coronary Syndromes in the Emergency Department: The 30-day Outcome Associated with Normal Left Ventricular Wall Motion. *Am Heart J* 2004;148:1096-1101 (PMID:15632899).
  23. Becker RC, **Alexander JH**, Dyke CK, Harrington RA. Development of DX-9065a, a Novel Direct Factor Xa Antagonist, in Cardiovascular Disease. *Thromb Haemost* 2004;92:1182-1193 (PMID:15583722).
  24. Borges-Neto S, Shaw L, **Alexander JH**, Smith WT IV, Tuttle RH, Chambless M, Coleman RE, Harrington RA, Califf RM. Incremental Prognostic Power of Single-photon Emission Computed Tomography Myocardial Perfusion Imaging in Patients with Known or Suspected Coronary Artery Disease. *Am J Cardiol* 2005;95:182-188 (PMID:15642549).
  25. **Alexander JH**, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA. First Experience with Direct, Selective Factor Xa Inhibition in Patients with Non-ST-elevation Acute Coronary Syndromes: Results of the XaNADU-ACS trial. *J Thromb Haemost* 2005;3:439-447 (PMID:15748230).
  26. Mehta RH, **Alexander JH**, Van de Werf F, Armstrong PW, Pieper KS, Garg J, Califf RM, Granger CB. Relationship of Incorrect Dosing of Fibrinolytic Therapy and Clinical Outcomes. *JAMA* 2005;293:1746-1750 (PMID:15827313).
  27. Becker RC, **Alexander JH**, Li Y, Robertson T, Kunitada S, Spencer FA, Harrington RA. Vascular Endothelial Tissue Factor Pathway Inhibitor Kinetics in Culture Following Exposure to DX-9065a—A Selective and Direct Factor Xa Inhibitor. *J Thromb Thrombolysis* 2004;18:193-197 (PMID:15815881).
  28. Meine TJ, Al-Khatib SM, **Alexander JH**, Granger CB, Kilaru R, Williams K, Ohman EM, Topol E, Califf RM. Incidence, Predictors, and Outcomes of High-degree Atrioventricular Block Complicating Acute Myocardial Infarction Treated with Thrombolytic Therapy. *J Am Heart Assoc* 2005;149:670-674 (PMID:15990751).
  29. Mehta RH, Califf RM, Garg J, Pieper KS, **Alexander JH**, Moliterno DJ, Van de Werf F, Ohman EM, White HD, Topol EJ, Granger CB. Association of Height with Outcomes in Patients with Acute Myocardial Infarction Receiving Reperfusion Therapy. *Am J Cardiol* 2005;95:1371-1375 (PMID:15904648).
  30. Mahaffey KW, Roe MT, Kilaru R, French JK, **Alexander JH**, Berdan LG, Van de Werf F, Simoons ML, Weaver WD, White HD, Lincoff AM, Kleiman NS, Topol EJ, Harrington RA. Characterization of Myocardial Infarction as an End Point in Two Large Trials of Acute Coronary Syndromes. *Am J Cardiol* 2005;95:1404-1408 (PMID:15950560).
  31. Bethel MA, **Alexander JH**, Lane J, Barkauskas C, Feinglos MN. Diabetes on a

- Cardiovascular Ward: Adherence to Current Recommendations. *South Med J* 2004;97:1031-1037 (PMID:15586590).
32. **Alexander JH**, Singh KP. Inhibition of Factor Xa: A Potential Target for the Development of New Anticoagulants. *Am J Cardiovasc Drugs* 2005;5:279-290 (PMID:16156684).
  33. **Alexander JH**, Ferguson TB, Joseph DM, Mack MJ, Wolf RK, Cohn LH, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Putnam W, Califf RM, Kouchoukos NT. The PROject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) Trial: Study Rationale, Design, and Baseline Patient Characteristics. *J Am Heart Assoc* 2005;150:643-649 (PMID:16209958).
  34. **The PREVENT IV Investigators**. Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery: PREVENT IV: A Randomized Controlled Trial. *JAMA* 2005;294:2446-454 (PMID:16287955). (Note: As Principal Investigator, I personally drafted the manuscript, oversaw all analyses, and served as corresponding author).
  35. Halabi A, **Alexander JH**, Shaw LK, Lorenz TJ, Liao L, Kong DF, Milano CA, Harrington RA, Smith PK. Relation of Early Saphenous Vein Graft Failure to Outcomes Following Coronary Artery Bypass Surgery. *Am J Cardiol* 2005;96:1254-1259 (PMID:16253593).
  36. Becker RC, **Alexander JH**, Dyke CK, Huang Y, Saint-Jacques H, Hasselblad V, Harrington RA, Bovill EG. Effect of the Novel Direct Factor Xa Inhibitor DX-9065a on Thrombin Generation and Inhibition Among Patients with Stable Atherosclerotic Coronary Artery Disease. *Thromb Res* 2006;117:439-446 (PMID:15882894).
  37. Galla JM, Mahaffey KW, Sapp SK, **Alexander JH**, Roe MT, Ohman EM, Granger CB, Armstrong PW. Elevated Creatine Kinase-MB with Normal Creatine Kinase Predicts Worse Outcomes in Patients with Acute Coronary Syndromes: Results from Four Large Clinical Trials. *J Am Heart Assoc* 2006;151:16-24 (PMID:16368286).
  38. **Alexander JH**, Harrington RA. Advances in Antithrombotic Therapy in Acute Myocardial Infarction: The ExTRACT-TIMI 25 and OASIS-6 Trials. *Curr Cardiol Rep* 2006;8:279-281 (PMID:16883666).
  39. Madsen LH, Christensen G, Serebruany VL, Hoen IB, Grieg Z, **Alexander JH**, Granger CB, Jaffe AS, Van Eyk JE, Atar D. Time Course of Degradation of Cardiac Troponin I in Patients with Acute ST-elevation Myocardial Infarction: The ASSENT-2 Troponin Substudy. *Circ Res* 2006;99:1141-1147 (PMID:17038641).
  40. Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, **Alexander JH**, Becker RC, Rusconi CP. First-in-human Experience of an Antidote-controlled Anticoagulant Using RNA Aptamer Technology: A Phase Ia Pharmacodynamic Evaluation of a Drug-antidote Pair for the Controlled Regulation of Factor IXa Activity. *Circulation* 2006;114:2490-2497 (PMID:17101847).
  41. Mahaffey KM, Roe MT, Kilaru R, **Alexander JH**, Van de Werf FJ, Califf RM, Simoons ML, Topol RJ. Creatine Kinase-MB Elevation after Coronary Artery Bypass Grafting Surgery in Patients with Non-ST-segment Elevation Acute Coronary Syndromes Predicts Worse Outcomes: Results from Four Large Clinical Trials. *Eur Heart J* 2007;28:425-432 (PMID:17267458).
  42. **TRIUMPH Investigators**. Tilarginine Acetate Injection in a Randomized International Study in Unstable Acute Myocardial Infarction Patients with Cardiogenic Shock (TRIUMPH): An International, Multicenter, Double-blind, Placebo-controlled Study. *JAMA*

- 2007;297:16571666 (PMID:17387132). (Note: As a member of the writing group, I personally drafted the manuscript, oversaw all analyses, and served as corresponding author).
43. Goyal A, **Alexander JH**, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Peterson ED; for the PREVENT IV Investigators. Outcomes Associated with the Use of Secondary Prevention Medications Following Coronary Artery Bypass Graft Surgery. *Ann Thorac Surg* 2007;83:993-1001 (PMID:17307447).
  44. Dzavik V, Cotter G, Reynolds HR, **Alexander JH**, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS; for the SHOCK-2 Investigators. Effect of Nitric Oxide Synthase Inhibition on Hemodynamics and Outcome of Patients with Persistent Cardiogenic Shock Complicating Acute Myocardial Infarction: A Phase 2 Dose-ranging Study. *Eur Heart J* 2007;28:1109-1116 (PMID:17459901).
  45. Cohen M, Bhatt DL, **Alexander JH**, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J; on behalf of the SEPIA-PCI Trial Investigators. Randomized, Doubleblind, Dose-ranging Study of Otamixaban, a Novel, Parenteral, Short-acting, Direct Factor Xa. Inhibitor in Percutaneous Coronary Intervention: The SEPIA-PCI Trial. *Circulation* 2007;115:2642-2651 (PMID:17502577).
  46. Magee MJ, **Alexander JH**, Hafley G, Ferguson TB, Gibson CM, Harrington RA, Peterson ED, Califf RM, Kouchoukos NT, Herbert MA, Mack MJ. Coronary Artery Bypass Graft Failure after On-pump and Off-pump Coronary Artery Bypass: Findings from PREVENT IV. *Ann Thorac Surg* 2008;85:494-500 (PMID:18222251).
  47. **The MEND-CABG II Investigators**. Efficacy and Safety of Pyrodoxal 5'-Phosphate (MC-1) in High-risk Patients Undergoing Coronary Artery Bypass Graft Surgery: The MEND-CABG II Randomized Clinical Trial. *JAMA* 2008;299:1777-1787 (PMID:18381567). (Note: As a member of the writing group, I personally drafted the manuscript, oversaw all analyses, and served as corresponding author).
  48. Olenchock SA, Karpaliotis D, Gibson WJ, Murphy SA, Southard MC, Ciaglo L, Buros J, Mack MJ, **Alexander JH**, Harrington RA, Califf RM, Kouchoukos NT, Ferguson TB, Gibson CM. Impact of Saphenous Vein Graft Radiographic Markers on Clinical Events and Angiographic Parameters. *Ann Thorac Surg* 2008;85:520-524 (PMID:18222256).
  49. Mehta RH, **Alexander JH**, Emery R, Ellis SJ, Hasselblad V, Khalil A, Carrier M, Harrington RA, Tardif JC; MEND-CABG II Investigators. A Randomized, Double-blind, Placebocontrolled, Multi-center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-risk Coronary Artery Bypass Graft Surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II—Study Design and Rationale. *J Am Heart Assoc* 2008;155:600-608 (PMID:18371465).
  50. Chan MY, Rusconi CP, **Alexander JH**, Tonkens RM, Harrington RA, Becker RC. A Randomized, Repeat-dose, Pharmacodynamic and Safety Study of an Antidote-controlled Factor IXa Inhibitor. *J Thromb Haemost* 2008;6:789-796 (PMID:18284597).
  51. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, **Alexander JH**,

- Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Phase 1b Randomized Study of Antidote-controlled Modulation of Factor IXa Activity in Patients with Stable Coronary Artery Disease. *Circulation* 2008;117:2865-874 (PMID:18506005).
52. Yau JM, **Alexander JH**, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N, Goyal A, Peterson ED, Gibson CM, Califf RM, Harrington RA, Ferguson TB. Impact of Perioperative Myocardial Infarction on Angiographic and Clinical Outcomes Following Coronary Artery Bypass Grafting (From PProject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). *Am J Cardiol* 2008;102:546-551 (PMID:18721510).
  53. Lopes RD, Piccini JP, Hylek EM, Granger CB, **Alexander JH**. Antithrombotic Therapy in Atrial Fibrillation: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2008;26:167-174 (PMID:18807225).
  54. Mehta RH, Hafley GE, Gibson CM, Harrington RA, Peterson ED, Mack MJ, Kouchoukos NT, Califf RM, Ferguson TB, **Alexander JH**; on behalf of the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT)-IV Investigators. Influence of Preoperative Renal Dysfunction on One-year Bypass Graft Patency and Two-year Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. *J Thorac Cardiovasc Surg* 2008;136:1149-1155 (PMID:19026795).
  55. Turer AT, Mahaffey KW, Honeycutt E, Tuttle RH, Shaw LK, Sketch MH, Smith PK, Califf RM, **Alexander JH**. Influence of Body Mass Index on the Efficacy of Revascularization in Patients with Coronary Artery Disease. *J Thorac Cardiovasc Surg* 2009;137:1468-1474 (PMID:19464466).
  56. **APPRAISE Steering Committee and Investigators**. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination with Antiplatelet Therapy after Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. *Circulation* 2009;119:2877-2885 (PMID:19470889). (Note: As Principal Investigator, I personally drafted the manuscript, oversaw all analyses, and served as corresponding author).
  57. Kraai EP, Lopes RD, **Alexander JH**, Garcia D. Perioperative Management of Anticoagulation: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2009;28:1622 (PMID:19242654).
  58. Bhatt DL, Kottke-Marchant K, **Alexander JH**, Peacock WF, Sabatine MS. Platelet Response in Practice: Applying New Insights and Tools for Testing and Treatment. *Cleve Clin J Med* 2009;76 Suppl 1:S24-32 (PMID:19332591).
  59. Houman Fekrazad M, Lopes RD, Stashenko GJ, **Alexander JH**, Garcia D. Treatment of Venous Thromboembolism: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2009;28:270-275 (PMID:19579012).
  60. Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RJ, Gibson CM, Mack MJ, Kouchoukos NT, Califf RM, **Alexander JH**. Endoscopic vs Open Vein-graft Harvesting in Coronary-artery Bypass Surgery. *N Engl J Med* 2009;361:234-244 (PMID:19605828).
  61. Katz JN, Stebbins AL, **Alexander JH**, Reynolds HR, Pieper KS, Ruzyllo W, Werdan K, Geppert A, Dzavik V, Van de Werf F, Hochman JS; for the TRIUMPH Investigators. Predictors of 30-day Mortality in Patients with Refractory Cardiogenic Shock Following Acute Myocardial Infarction Despite a Patent Infarct Artery. *J Am Heart Assoc* 2009;158:680687 (PMID:19781431).



62. Al-Khatib SA, Hafley G, Harrington RA, Mack MJ, Ferguson TB, Peterson ED, Califf RM, Kouchoukos, NT, **Alexander JH**. Patterns of Management of Atrial Fibrillation Complicating Coronary Artery Bypass Grafting: Results from the PROject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. *J Am Heart Assoc* 2009;158:792-798 (PMID:19853700).
63. Lopes RD, **Alexander JH**, Al-Khatib SM, Ansell J, Diaz R, Easton D, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJV, Verheugt FWA, Wallentin L. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial: Design and Rationale. *J Am Heart Assoc* 2010;159:331-339 (PMID:20211292).
64. Krishnan A, Lopes RD, **Alexander JH**, Becker RC, Goldstein LB. Antithrombotic Therapy for Ischemic Stroke: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2010;293:368-377 (PMID:20127273).
65. Rao SV, Melloni C, Myles-DiMauro S, Broderick S, Kosinski AS, Kleiman NS, Dzavik V, Tanguay JF, Chandna H, Gammon R, Rivera E, **Alexander JH**, Fier I, Roach J, Becker RC; for the EMINENCE Investigators. Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) Trial. *Circulation* 2010;121:1713-1721 (PMID:20368520).
66. Gharacholou SM, Lopes RD, Washam JB, Newby LK, Wallentin L, **Alexander JH**. Antithrombotic Therapy in Acute Coronary Syndromes: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2010;29:516-528 (PMID:20091089).
67. Frederich R, **Alexander JH**, Fiedorek FT, Donovan M, Berglind N, Harris S, Chen R, Wolf R, Mahaffey KW. A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes. *Postgrad Med* 2010;122:16-27 (PMID:20463410).
68. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, **Alexander JH**, Harrington RA, Rusconi CP, Becker RC. First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention. *Circulation* 2010;122:614-622 (PMID:20660806).
69. Becker RC, **Alexander JH**, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC. Effect of Apixaban, an Oral and Direct Factor Xa Inhibitor, on Coagulation Activity Biomarkers following Acute Coronary Syndrome. *Thromb Haemost* 2010;104:976-983 (PMID:20806117).
70. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, Ardissino D, Califf RM, Granger CB, Ohman EM, **Alexander JH**. Antiarrhythmic Drug Therapy for Sustained Ventricular Arrhythmias Complicating Acute Myocardial Infarction. *Crit Care Med* 2011;39:78-83 (PMID:20959785).
71. Mehta RH, Stebbins A, Lopes RD, Rao SV, Bates ER, Pieper KS, Armstrong PW, Van de Werf F, White HD, Topol EJ, Califf RM, **Alexander JH**, Granger CB. Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. *Am J Med* 2011;124:48-57 (PMID:21187185).
72. Stashenko G, Lopes RD, Garcia D, **Alexander JH**, Tapson VF. Prophylaxis for Venous Thromboembolism: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2011;31:122-132 (PMID:20936495).

73. Domanski MJ, Mahaffey K, Hasselblad V, Brener SJ, Smith PK, Hillis G, Engoren M, **Alexander JH**, Levy JH, Chaitman BR, Broderick S, Mack MJ, Pieper KS, Farkouh ME. Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery. *JAMA* 2011;305:585-597 (PMID:21304084).
74. Povsic TJ, Cohen MG, Mehran R, Buller CE, Bode C, Cornel JH, Kasprzak JD, Montalescot G, Joseph D, Wargin WA, Rusconi CP, Zelenkofske SL, Becker RC, **Alexander JH**. A Randomized, Partially-Blinded, Multicenter, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System in Patients with Acute Coronary Syndromes: The Design of the RADAR Phase IIb Trial. *J Am Heart Assoc* 2011;161:261-268 (PMID:21315207).
75. Leiria TL, Lopes RD, Williams JB, Katz JN, Kalil RA, **Alexander JH**. Antithrombotic Therapies in Patients with Prosthetic Heart Valves: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2011;31:514-522 (PMID:21327503).
76. Povsic TJ, Cohen MG, Chan MY, Zelenkofske SL, Wargin WA, Harrington RA, **Alexander JH**, Rusconi CP, Becker RC. Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design. *J Thromb Thrombolysis* 2011;32:2131 (PMID:21503856).
77. Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, Gibson CM, Harrington RA, Califf RM, Peterson ED, **Alexander JH**; on behalf of the PREVENT-IV Investigators. Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. *Circulation* 2011;124:280-288 (PMID:21709060).
78. Povsic TJ, Wargin WA, **Alexander JH**, Krasnow J, Krolick M, Cohen MG, Mehran R, Buller CE, Bode C, Zelenkofse SL, Rusconi CP, Becker RC. Pegnivacogin Results in Near Complete FIX Inhibition in ACS Patients: RADAR Pharmacokinetic and Pharmacodynamic Substudy. *Eur Heart J* 2011;32:2412-2419 (PMID:21724623).
79. **Alexander JH**, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Luis Leiva-Pons J, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldles M, Lawrence J, Harrington RA, Wallentin L; for the APPRAISE-2 Investigators. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. *N Engl J Med* 2011;365:699-708 (PMID:21780946).
80. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, **Alexander JH**. Chromogenic Laboratory Assays to Measure the Factor Xa-Inhibiting Properties of Apixaban—An Oral, Direct and Selective Factor Xa Inhibitor. *J Thromb Thrombolysis* 2011;32:183-187 (PMID:21516308).
81. Granger CB, **Alexander JH**, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldles M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopes-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L; for the ARISTOTLE Committees and Investigators.

- Apixaban vs Warfarin in Patients with Atrial Fibrillation. *N Engl J Med* 2011;365:981-992 (PMID:21870978).
82. Lobato RL, White WD, Mathew JP, Newman MF, Smith PK, McCants CB, **Alexander JH**, Podgoreanu MV. Thrombomodulin Gene Variants are Associated with Increased Mortality following Coronary Artery Bypass Surgery in Replicated Analysis. *Circulation* 2011;124:S143-8 (PMID:21911804).
  83. Saito S, Prpic R, Popma JJ, **Alexander JH**, Krucoff MW; for the Endeavor Japan Investigators. The Clinical Evaluation of the Endeavor Zotarolimus Eluting Coronary Stent in Japanese Patients with De Novo Native Coronary Artery Lesions: Primary Results and Threeyear Follow-up of the ENDEAVOR Japan Study. *Cardiovasc Revasc Med* 2011;12:273-9 (PMID: 21367669).
  84. Povsic TJ, O'Connor CM, Henry T, Taussig A, Kereiakes DJ, Fortuin D, Niederman A, Schatz R, Spencer R, Owens D, Banks M, Joseph D, Roberts R, **Alexander JH**, Sherman W. A Double-blind, Randomized, Controlled, Multicenter Study to Assess the Safety and Cardiovascular Effects of Skeletal Myoblast Implantation by Catheter Delivery in Patients with Chronic Heart Failure after Myocardial Infarction. *J Am Heart Assoc* 2011;162:654-662 (PMID:21982657).
  85. Vavalle JP, Stevens SR, Hassinger N, Cohen MG, Arnold A, Kandzari D, Aguirre FV, Gretler DD, **Alexander JH**. The Kinetics of Integrilin Limited by Obesity: A Multicenter Randomized Pharmacokinetic and Pharmacodynamic Clinical Trial. *J Am Heart Assoc* 2011;162:996-1002 (PMID:22137072; PMCID:PMC3611663).
  86. Smith PK, Michler RE, Woo YJ, **Alexander JH**, Puskas JD, Parides MK, Hahn RT, Williams JB, Dent JM, Ferguson TB Jr, Moquete E, Rose EA, Page P, Jeffries NO, O'Gara PT, Ascheim DD. Design, Rationale, and Initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: A Report from the Cardiothoracic Surgical Trials Network. *J Thorac Cardiovasc Surg* 2011;143:111-117 (PMID:21788032).
  87. Mehta RH, Stebbins AS, Lopes RD, Califf RM, Pieper KS, Armstrong PW, Van de Werf F, Hochman JS, White HD, Topol EJ, **Alexander JH**, Granger CB. Comparison of Incidence of Bleeding and Mortality of Men vs Women with ST-Elevation Myocardial Infarction Treated with Fibrinolysis. *Am J Cardiol* 2012;109:320-326 (PMID:22078221).
  88. Lopes RD, Mehta RH, Hafley GE, Williams JB, Mack MJ, Peterson ED, Allen KB, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, **Alexander JH** on behalf of the Project of Ex Vivo Vein Graft Engineering via Transfection IV (PREVENT IV) Investigators. Relationship between Vein Graft Failure and Subsequent Clinical Outcomes after Coronary Artery Bypass Surgery. *Circulation* 2012;125:749-756 (PMID:22238227).
  89. Al-Khatib SM, **Alexander JH**, Lopes RD, Mahaffey KW, Patel MR, Granger CB. Promise of Factor Xa Inhibition in Atrial Fibrillation. *Curr Cardiol Rep* 2012;14:70-8 (PMID: 22109539).
  90. Wiggins NB, Granger CB, **Alexander JH**. Novel Oral Anticoagulants after Acute Coronary Syndromes. *Cardiovasc Drugs Ther* 2012;26:265-271 (PMID:22434545).
  91. Koshizaka M, Green JB, **Alexander JH**. Glycemic Management in Diabetes and the Associated Cardiovascular Risk. *Circ J* 2012;76:1572-1580 (PMID:22789974).
  92. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, **Alexander JH**, Diener HC for the

- ARISTOTLE Committees and Investigators. Apixaban Compared with Warfarin in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischaemic Attack: a Subgroup Analysis of the ARISTOTLE Trial. *Lancet Neurol* 2012;11:503-511 (PMID:22572202).
93. Williams JB, Peterson ED, Brennan JM, Sedrakyan A, Tavriss D, **Alexander JH**, Lopes RD, Dokholyan RS, Zhao Y, O'Brien SM, Michler RE, Thourani VH, Edwards FH, Duggirala H, Gross T, Marinac-Dabic D, Smith PK. Association Between Endoscopic vs Open Vein-Graft Harvesting and Mortality, Wound Complications, and Cardiovascular Events in Patients Undergoing CABG Surgery. *JAMA* 2012;308:475-484 (PMID:22851114).
  94. Hess CN, Becker RC, **Alexander JH**, Lopes RD. Antithrombotic Therapy in Heparin-Induced Thrombocytopenia; Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2012;34:552-561 (PMID:22843169).
  95. Vavalle JP, Rusconi CP, Zelenkofske S, Wargin WA, **Alexander JH**, Becker RC. A Phase 1 Ascending Dose Study of a Subcutaneously Administered Factor IXa Inhibitor and its Active Control Agent. *J Thromb Haemost* 2012;10:1303-1311 (PMID:22500821).
  96. Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, **Alexander JH**. Edifoligide and Long-term Outcomes after Coronary Artery Bypass Grafting: Project of Ex-vivo Vein Graft Engineering via Transfection IV (PREVENT-IV) 5-year Results. *J Am Heart Assoc* 2012;164:379-386 (PMID:22980305).
  97. Hohnloser SH, Hijazi Z, Thomas L, **Alexander JH**, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of Apixaban when Compared with Warfarin in Relation to Renal Function in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Eur Heart J* 2012;33:2821-2830 (PMID:22933567).
  98. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina RD, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJV, Mohan P, Vinereanu D, **Alexander JH**. Efficacy and Safety of Apixaban Compared with Warfarin According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation: A Secondary Analysis of a Randomized Clinical Trial. *Lancet* 2012;380:1749-1758 (PMID:23036896).
  99. Hess CN, Broderick S, Piccini JP, Alexander KA, Newby LK, Shaw LK, Mahaffey KW, **Alexander JH**, Peterson ED, Granger CB, Lopes RD. Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Older Patients. *J Am Heart Assoc* 2012;164:607-615 (PMID: 23067921; PMCID:PMC3777661).
  100. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, Mehran R, Bode C, Buller CE, Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeyer U, Natarajan M, Delarche N, Zelenkofske SL, Becker RC, **Alexander JH**. A Phase 2 Randomized, Partially Blinded Active-Controlled Study Assessing the Efficacy and Safety of Variable Anticoagulation Reversal Using the REG1 System in Patients with Acute Coronary Syndromes: Results of the RADAR Trial. *Eur Heart J* 2013;34:2481-2489 (PMID:22859796).
  101. Harskamp RE, Lopes RD, Baisden CE, de Winter RJ, **Alexander JH**. Saphenous Vein Graft Failure after Coronary Artery Bypass Surgery: Pathophysiology, Management and Future Directions. *Ann Surg* 2013;257:824-833 (PMID:23574989).
  102. Oldgren J, Wallentin L, **Alexander JH**, James S, Jönelid B, Steg G, Sundström J. New Oral

- Anticoagulants in Addition to Single or Dual Antiplatelet Therapy after an Acute Coronary Syndrome: A Systematic Review and Meta-analysis. *Eur Heart J* 2013;34:1670-1680 (PMID:23470494).
103. Williams JB, Lopes RD, Hafley GE, Bruce Ferguson T Jr, Mack MJ, Michael Gibson C, Harrington RA, Peterson ED, Smith PK, Mehta RH, **Alexander JH**. Relationship between Postoperative Clopidogrel Use and Subsequent Angiographic and Clinical Outcomes Following Coronary Artery Bypass Grafting. *J Thromb Thrombolysis* 2013;36:384-393 (PMID:23543398).
  104. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M, **Alexander JH**, Lopes RD, Wojdyla DM, Wallentin L, Granger CB. Left Ventricular Systolic Dysfunction, Heart Failure and the Risk of Stroke and Systemic Embolism in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Circ Heart Fail* 2013;6:451-460 (PMID:23575255).
  105. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, **Alexander JH**, Flaker G, Hanna M, Granger CB. Outcomes of Apixaban vs. Warfarin by Type and Duration of Atrial Fibrillation: Results from the ARISTOTLE Trial. *Eur Heart J* 2013;34:2464-2471 (PMID:23594592).
  106. Subherwal S, Ohman ME, Mahaffey KW, Rao SV, **Alexander JH**, Wang TY, Alexander KP, Hasselblad V, Roe MT. Incorporation of Bleeding as an Element of the Primary Composite Endpoint in Clinical Trials of Antithrombotic Therapies in Patients with Non-ST Segment Elevation Acute Coronary Syndrome – Validity, Pitfalls, and Future Approaches. *J Am Heart Assoc* 2013;165:644-654 (PMID:23622901).
  107. Harskamp RE, Williams JB, Hill RC, de Winter RJ, **Alexander JH**, Lopes RD. Saphenous Vein Graft Failure and Clinical Outcomes: Towards a Surrogate Endpoint in Patients Following Coronary Artery Bypass Surgery? *J Am Heart Assoc* 2013;165:639-643 (PMID:23622900).
  108. Wallentin L, Lopes RD, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, **Alexander JH**, Alins M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJV, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. On Behalf of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. *Circulation* 2013;127:2166-2176 (PMID:23640971).
  109. **Alexander JH**, Peterson ED. Surgery: Translating Trials to Clinical Practice in Cardiac Surgery. *Nat Rev Cardiol* 2013;10:306-307 (PMID:23648784).
  110. Williams ES, Thompson VP, Chiswell KE, **Alexander JH**, White HD, Ohman EM, Al-Khatib SM. Rate vs Rhythm Control and Outcomes in Patients with Atrial Fibrillation and Chronic Kidney Disease: Data from the GUSTO-III Trial. *Cardiol J* 2013;20:439-446 (PMID:23913464).
  111. Steinberg BA, Hasselblad V, Atwater BD, Bahnson TD, Washam JB, **Alexander JH**, Daubert JP, Piccini JP. Dabigatran for Periprocedural Anticoagulation Following Radiofrequency Ablation for Atrial Fibrillation: A Meta-Analysis of Observational Studies. *J Interv Card Electrophysiol* 2013;37:212-221 (PMID:23881249).

112. **Alexander JH**, Levy E, Lawrence J, Hanna M, Waclawski AP, Wang J, Califf RM, Wallentin L, Granger CB. Documentation of Study Medication Dispensing in a Prospective Large Randomized Clinical Trial: Experiences from the ARISTOTLE Trial. *J Am Heart Assoc* 2013;166:559-665 (PMID:24016507).
113. Garcia DA, Wallentin L, Lopes RD, Thomas L, **Alexander JH**, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban vs Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial. *Am Heart J* 2013;166:549-558 (PMID:24016506).
114. **Alexander JH**, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM, Granger CB, Wallentin L. Apixaban vs. Warfarin with Concomitant Aspirin In Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Eur Heart J* 2014;35:224-232 (PMID:24144788).
115. Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, **Alexander JH**. Effect of Levosimendan on Survival and Adverse Events after Cardiac Surgery: A Meta-Analysis. *J Cardiothorac Vasc Anesth* 2013;27:1224-232 (PMID:24050857).
116. Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, **Alexander JH**, Lewis BS, Aylward PE, Verheugt FW, Keltai M, Diaz R, Hanna M, Granger CB, Wallentin L. Apixaban in Patients with Atrial Fibrillation and Prior Coronary Artery Disease: Insights from the ARISTOTLE Trial. *Int J Cardiol* 2013;170:215-220 (PMID:24192334).
117. Vavalle JP, Povsic TJ, Aberle LH, Zelenkofske SL, Mehran R, Kasprzak JD, Bode C, Buller CE, Montalescot G, Cornel JH, Becker RC, **Alexander JH**, Cohen MG. Safety of Very Early Sheath Removal in Patients Treated with REG1 for Acute Coronary Syndromes: Insights from the RADAR Trial. *J Invasive Cardiol* 2013;25:593-599 (PMID:24184894).
118. de Souza Brito F, Lopes RD, **Alexander JH**. The Safety and Efficacy of Apixaban: Where Do We Stand in 2013? *Expert Opin Drug Saf* 2013;12:559-567 (PMID:23662974).
119. Harskamp RE, Zheng Z, **Alexander JH**, Williams JB, Xian Y, Halkos ME, Brennan JM, de Winter RJ, Smith PK, Lopes RD. Status Quo of Hybrid Coronary Revascularization for MultiVessel Coronary Artery Disease. *Ann Thorac Surg* 2013;96:2268-2277 (PMID:24446561).
120. Harskamp RE, Bonatti JO, Zhao DX, Puskas JD, de Winter RJ, **Alexander JH**, Halkos ME. Standardizing Definitions for Hybrid Coronary Revascularization. *J Thorac Cardiovasc Surg* 2014;147:556-560 (PMID:24280716).
121. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, **Alexander JH**, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJV, Granger CB, on behalf of the ARISTOTLE Investigators. High-Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation During Treatment with Apixaban or Warfarin. *J Am Coll Cardiol* 2014;63:52-61 (PMID:24055845).
122. van Diepen S, Reynolds HR, Stebbins A, Lopes RD, Dzavik V, Ruzyllo W, Geppert A, Widimsky P, Ohman EM, Parrillo JE, Dauerman HL, Baran DA, Hochman JS, **Alexander JH**. Incidence and Outcomes Associated with Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock. *Crit Care Med* 2014;42:281-288 (PMID:23982033).

123. Povsic TJ, Vavalle JP, **Alexander JH**, Aberle LH, Zelenkofske SL, Becker RC, Buller CE, Cohen MG, Cornel JH, Kasprzak JD, Montalescot G, Fail PS, Sarembock IJ, Mehran R. Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Results from the phase II RADAR-PCI study. *EuroIntervention* 2014;10:431-438 (PMID:24929350).
124. Harskamp RE, **Alexander JH**, Schulte PJ, Jones S, Williams JB, Mack MJ, Peterson ED, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, de Winter RJ, Lopes RD. Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes after Coronary Artery Bypass Surgery. *Ann Thorac Surg* 2014;97:824-830 (PMID:24360877).
125. Hijazi Z, Siegbahn A, Andersson U, Granger CB, **Alexander JH**, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJV, Wallentin L., on behalf of the ARISTOTLE Investigators. High Sensitivity Troponin I for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Circulation* 2014;129:625-634 (PMID:24226808).
126. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, **Alexander JH**, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De CR, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanan F. L Response to letter regarding article, Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. *Circulation* 2014;129:e21-22 (PMID:24421367).
127. Harskamp RE, Bagai A, Halkos ME, Rao SV, Bachinsky WB, Patel RM, de Winter RJ, Peterson ED, **Alexander JH**, Lopes RD. Clinical Outcomes after Hybrid Coronary Revascularization versus Coronary Artery Bypass Surgery: A Meta-Analysis of 1,190 Patients. *J Am Heart Assoc* 2014;167:585-592 (PMID:24655709).
128. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, **Alexander JH**, Granger CB; ARISTOTLE Committees and Investigators. Efficacy and Safety of Apixaban in Patients after Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). *J Am Coll Cardiol* 2014;63:1082-1087 (PMID:24211508).
129. Nelson JA, Vavalle JP, May CH, Zhang A, Newby LK, Shaw LK, Al-Khatib SM, **Alexander JH**, Granger CB, Lopes RD. Warfarin Use and Long-Term Outcomes in Patients with Acute Myocardial Infarction and Atrial Fibrillation. *J Thromb Thrombolysis* 2014;37:331-337 (PMID:23733104).
130. Hylek EM, Held C, **Alexander JH**, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. *J Am Coll Cardiol* 2014;63:2141-2147 (PMID:24657685).
131. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, Lopes RD, **Alexander JH**, Mathew JP, Velazquez EJ, Milano CA, Smith PK. Surgical Revascularization is Associated with Maximal Survival in Patients with Ischemic Mitral Regurgitation: A 20-Year Experience. *Circulation* 2014;129:2547-2556 (PMID:24744275).

132. Mahaffey KW, Wojdyla DM, Pieper KS, Tricoci P, **Alexander JH**, Lincoff AM, Brennan DM, Bhatt DL, Wallentin L, Harrington RA. Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients with Chronic Stable Atherosclerosis. *Clin Cardiol* 2014;37:337-342 (PMID:24615711).
133. van Diepen S, Brennan JM, Hafley GE, Reyes EM, Allen KB, Ferguson TB, Peterson ED, Williams JB, Gibson CM, Mack MJ, Kouchoukos NT, **Alexander JH**, Lopes RD. Endoscopic Harvesting Device Type and Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. *Ann Surg* 2014;260:402-408 (PMID:24368640).
134. Povsic TJ, Vavalle JP, **Alexander JH**, Aberle LH, Zelenkofske SL, Becker RC, Buller CE, Cohen MG, Cornel JH, Kasprzak JD, Montalescot G, Fail PS, Sarembock IJ, Mehran R. Use of the REG1 Anticoagulation System in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results from the phase II RADAR-PCI study *EuroIntervention* 2014;10:431-438 (PMID:24929350).
135. Hess CN, Roe MT, Gibson CM, J Temple R, Pencina MJ, Zarin DA, Anstrom KJ, **Alexander JH**, Sherman RE, Fiedorek FT, Mahaffey KW, Lee KL, Chow SC, Armstrong PW, Califf RM. Independent Data Monitoring Committees: Preparing a Path for the Future. *J Am Heart Assoc* 2014;168:135-141 (PMID:25066551).
136. Iribame A, Change H, **Alexander JH**, Gillinov AM, Moquete E, Puskas JD, Bagiella E, Acker MA, Mayer ML, Ferguson TB, Burks S, Perrault LP, Welsh S, Johnston KC, Murphy M, DeRose JJ, Neill A, Dobrev E, Baio KT, Taddei-Petters W, Moskowitz AJ, O’Gara PT. Readmissions after Cardiac Surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. *Ann Thorac Surg* 2014;98:1274-80 (PMID: 25173721).
137. Smith PK, Puskas JD, Ascheim DD, Voisline P, Gelijns AC, Moskowitz AJ, Hung JW, Parides MK, Ailawadi G, Perrault LP, Acker MA, Argenziano M, Thourani V, Overbey JR, Bagiella E, Dagenais F, Blackstone EH, Kron IL, Goldstein DJ, Rose EA, Moquete EC, Jeffries N, Gardner TJ, O’Gara PT, **Alexander JH**, Michler RE. Surgical Treatment of Moderate Ischemic Mitral Regurgitation. *N Engl J Med* 2014;371:2178-2188 (PMID:25405390).
138. Harskamp RE, Walker PF, **Alexander JH**, Xian Y, Liberman HA, de Winter RJ, Vassiliades TA, Peterson ED, Puskas JD, Halkos ME. Clinical Outcomes of Hybrid Coronary Revascularization versus Coronary Artery Bypass Surgery in Patients with Diabetes Mellitus. *J Am Heart Assoc* 2014;168:471-478 (PMID:25262256).
139. Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, **Alexander JH**, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical Events after Transitioning from Apixaban vs Warfarin to Warfarin at the End of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *J Am Heart Assoc* 2015;169:25-30 (PMID:25497244).
140. Koshizaka M, Lopes RD, Reyes EM, Gibson CM, Schulte PJ, Hafley GE, Hernandez AF, Green JB, Kouchoukos NT, Califf RM, Ferguson TB, Peterson ED, **Alexander JH**. Longterm Clinical and Angiographic Outcomes in Patients with Diabetes Undergoing Coronary Artery Bypass Graft Surgery: Results from the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. *J Am Heart Assoc* 2015;169:175-184 (PMID:25497264).
141. Wallentin L, Hijazi Z, Andersson U, **Alexander JH**, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A; ARISTOTLE Investigators.



- Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Circulation* 2014;130:1847-18458 (PMID:25294786).
142. Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack MJ, Califf RM, Kouchoukos NT, Peterson ED, Alexander JH. Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights from PREVENT IV. *Circulation* 2014;130:1445-1451 (PMID: 25261549).
  143. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanan F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and Clinical Outcomes in Patients Treated with Apixaban vs Warfarin Undergoing Procedures. *Blood* 2014;124:36923698 (PMID:25320240).
  144. Greco G, Shi W, Michler RE, Meltzer DO, Ailawadi G, Hohmann SF, Thourani VH, Argenziano M, **Alexander JH**, Sankovic K, Gupta L, Blackstone EH, Acker MA, Russo MJ, Lee A, Burks SG, Gelijns AC, Bagiella E, Moskowitz AJ, Gardner TJ. Costs Associated with Health Care Associated Infections in Cardiac Surgery. *J Am Coll Cardiol* 2015;65:15-23 (PMID: 25572505).
  145. Christersson C, Wallentin L, Andersson U, **Alexander JH**, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A. D-Dimer and Risk of Thromboembolic and Bleeding Events in Patients with Atrial Fibrillation: Observations from the ARISTOTLE Trial. *J Thromb Haemost* 2014;12:14011412 (PMID: 24942912).
  146. Vavalle JP, Rusconi CP, Zelenkofske S, Wargin WA, Ortel TL, **Alexander JH**, Povsic TJ, Becker RC. The Effect of the REG2 Anticoagulation System on Thrombin Generation Kinetics: A Pharmacodynamic and Pharmacokinetic First-in-Human Study. *J Thromb Thrombolysis* 2014;38:275-284 (PMID: 24880800).
  147. Harskamp RE, **Alexander JH**, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB, Lopes RD. Vein Graft Preservation Solutions, Patency, and Outcomes after Coronary Artery Bypass Graft Surgery: Follow-up from the PREVENT IV Randomized Clinical Trial. *JAMA Surg* 2014;149:798-805 (PMID:25073921).
  148. Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, Bahit MC, Gersh BJ, Hanna M, Horowitz J, Lopes RD, Wallentin L, Xavier D, **Alexander JH**; ARISTOTLE Investigators. Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation from East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *J Am Heart Assoc* 2014;168:303-309 (PMID:25173541).
  149. Steinberg BA, Schulte PJ, Hofmann P, Ersboll M, **Alexander JH**, Broderick-Forsgren K, Anstrom KJ, Granger CB, Piccini JP, Velazquez EJ, Shah BR. Outcomes after Non-emergent Electrical Cardioversion for Atrial Arrhythmias. *Am J Cardiol* 2015;115:1407-1414 (PMID:25784514).
  150. Ezekowitz JA, Lewis BS, Lopes RD, Wojdyla DM, McMurray JJV, Hanna M, Atar D, Bahit MC, Keltai M, Lopez-Sendon JL, Pais P, Ruzyllo W, Wallentin L, Granger CB, **Alexander**

- JH.** Clinical Outcomes of Patients with Diabetes and Atrial Fibrillation treated with Apixaban: Results from the ARISTOTLE Trial. *Eur Heart J Cardiovasc Pharmacother* 2015;1:86-94 (PMID:27533976).
151. Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, **Alexander JH**, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJV, Wallentin L. Comparison of Cardiac Troponins I and T Measured with High Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation - An ARISTOTLE Substudy. *Clin Chem* 2015;61:368-378 (PMID:25451868).
152. Held C, Hylek EM, **Alexander JH**, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical Outcomes and Management Associated with Major Bleeding in Patients with Atrial Fibrillation Treated with Apixaban or Warfarin: Insights from the ARISTOTLE Trial *Eur Heart J* 2015;36:1264-72 (PMID: 25499871).
153. Povsic TJ, Broderick S, Anstrom K, Shaw LS, Ohman EM, Eisenstein E, Smith PB, **Alexander JH**. Predictors of Long-term Clinical Endpoints in Patients with Refractory Angina. *J Am Heart Assoc* 2015;4:e001287 (PMID:25637344).
154. Cornel JH, Lopes RD, James S, Stevens SR, Neely ML, Liaw D, Miller J, Mohan P, Amerena J, Raev D, Huo Y, Urina-Triana M, Gallegos Cazorla A, Vinereanu D, Fridrich V, Harrington RA, Wallentin L, **Alexander JH**; APPRAISE-2 Study Group. Anticoagulant Therapy and Outcomes in Patients with Prior or Acute Heart Failure and Acute Coronary Syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. *Am Heart J* 2015;169:531-538 (PMID:25819860).
155. Mahaffey KW, Hager R, Wojdyla D, White HD, Armstrong PW, **Alexander JH**, Tricoci P, Lopes RD, Ohman EM, Roe MT, Harrington RA, Wallentin L. Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence; Predictors and Clinical Outcomes. *J Am Heart Assoc* 2015;4:e001512 (PMID:26089177).
156. Roe MT, Mahaffey KW, Ezekowitz JA, **Alexander JH**, Goodman SG, Hernandez AF, Temple T, Berdan L, Califf RM, Harrington RA, Peterson ED, Armstrong PW. The future of Cardiovascular Clinical Research in North America and Beyond - Addressing Challenges and Leveraging Opportunities Through Unique Academic and Grassroots Collaborations. *J Am Heart Assoc* 2015;169:743-750 (PMID:260271610).
157. Tricoci P, D'Andrea DM, Gurbel PA, Yao Z, Cuchel M, Winston B, Schott R, Weiss R, Blazing MA, Cannon L, Bailey A, Angiolillo DJ, Gille A, Shear CL, Wright SD, **Alexander JH**. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients with Atherosclerosis: Safety and Pharmacokinetic Results from a Phase 2a Randomized Clinical Trial. *J Am Heart Assoc* 2015;4:e002171 (PMID:26307570).
158. Kragholm K, Halim SA, Yang Q, Schulte PJ, Hochman JS, Melloni C, Mahaffey KW, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Ohman EM, Van de Werf F, Tricoci P, **Alexander JH**, Giugliano RP, Newby LK. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights from Clinical Trials Over 17 Years. *Circ Cardiovasc Qual Outcomes* 2015;8:357-367 (PMID:26152683).

159. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De CR, Goto S, Ruzyllo W, Zhu J, Granger CB, **Alexander JH**. Apixaban in Comparison with Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Circulation* 2015;132:624-632 (PMID:26106009).
160. Khan R, Lopes RD, Neely ML, Stevens SR, Harrington RA, Diaz R, Cools F, Jansky P, Montalescot G, Atar D, Lopez-Sendon J, Flather M, Liaw D, Wallentin L, **Alexander JH**, Goodman SG. Characterising and Predicting Bleeding in High-Risk Patients with an Acute Coronary Syndrome. *Heart* 2015;101:1475-1484 (PMID:26109589).
161. Williams JB, Harskamp RE, Bose S, Lawson JH, **Alexander JH**, Smith PK, Lopes RD. The Preservation and Handling of Vein Grafts in Current Surgical Practice: Findings of a Survey Among Cardiovascular Surgeons of Top-Ranked US Hospitals. *JAMA Surg* 2015;150:681683 (PMID:25970819).
162. Samad Z, Shaw LK, Phelan M, Ersboll M, Risum N, Al-Khalidi HR, Glower DD, Milano CA, **Alexander JH**, O'Connor CM, Wang A, Velazquez EJ. Management and Outcomes in Patients with Moderate or Severe Functional Mitral Regurgitation and Severe Left Ventricular Dysfunction. *Eur Heart J* 2015;36:2733-2741 (PMID:26233850).
163. Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, Hagstrom E, Bhatt DL, Husted S, Goodman SG, Lewis BS, Verheugt FW, De CR, Ogawa H, Wallentin L, **Alexander JH**. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial. *J Am Coll Cardiol* 2015;66:777-787 (PMID:26271059).
164. Rao MP, Halvorsen S, Wojdyla D, Thomas L, **Alexander JH**, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients with Atrial Fibrillation: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *J Am Heart Assoc* 2015;4:e002015 (PMID:26627878).
165. Vinereanu D, Stevens SR, **Alexander JH**, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical Outcomes in Patients with Atrial Fibrillation According to Sex During Anticoagulation with Apixaban or Warfarin: a Secondary Analysis of a Randomized Controlled Trial. *Eur Heart J* 2015;36:3268-3275 (PMID:26371113).
166. Bel A, Davidson S, Helies JM, Stimmer L, Fremes S, Zelenkofske S, Rusconi C, **Alexander JH**, Alexander D, Menasche P, and Pepper J. Inhibition of Factor IXa by the Pegnivacogin System during Cardiopulmonary Bypass: A Potential Substitute for Heparin. A Study in Baboons. *Eur J Cardiothorac Surg* 2016;49:682-689 (PMID:25953802).
167. Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Lanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, **Alexander JH** for the REGULATE-PCI Investigators. Effect of the REG1 Anticoagulation System versus Bivalirudin on Outcomes after Percutaneous Coronary Intervention (REGULATE-PCI): a Randomised Clinical Trial. *Lancet* 2016;387:349-356 (PMID:26547100).

168. Zimmerman A, Lopes RD, Stebbins AL, Guimarães PO, Haque G, Melloni C, Trollinger K, James SK, **Alexander JH**, Tricoci P, Roe MT, Ohman EM, Mahaffey KW, Held C, Tinga B, Pieper KS, Alexander KP. Pooled Analysis of Adverse Event Collection from Four Acute Coronary Syndrome Trials. *J Am Heart Assoc* 2016;174:60-67 (PMID:26995371).
169. Kragholm K, Goldstein SA, Yang Q, Lopes RD, Schulte PJ, Bernacki GM, White HD, Mahaffey KW, Giugliano RP, Armstrong PW, Harrington RA, Tricoci P, Van de Werf F, **Alexander JH**, Alexander KP, Newby LK. Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. *Circulation* 2016;133:1560-1573 (PMID:26957532; PMCID: PMC: 4856566).
170. Hijazi Z, Aulin J, Andersson U, **Alexander JH**, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L; ARISTOTLE Investigators. Biomarkers of Inflammation and Risk of Cardiovascular Events in Anticoagulated Patients with Atrial Fibrillation. *Heart* 2016;102:508-517 (PMID:26839066).
171. Ganson NJ, Povsic TJ, Sullenger BA, **Alexander JH**, Zelenkofske SL, Sailstad JM, Rusconi CP, Hershfield MS. Pre-Existing Anti-Polyethylene Glycol Antibody Linked to First Exposure Allergic Reactions to Pegnivacogin, a PEGylated RNA aptamer. *J Allergy Clin Immunol* 2016;137:1610-1613 (PMID:26688515).
172. Harskamp RE, **Alexander JH**, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith PK, Lopes RD. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights from the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. *Circulation* 2016;133:131-138 (PMID:26647082, PMCID:PMC4814323).
173. **Alexander JH**, Smith PK. Coronary-Artery Bypass Grafting. *N Engl J Med* 2016;374:1954-1964 (PMID:27192673).
174. De Caterina R, Andersson U, **Alexander JH**, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanan F, Lopes RD, López-Sendón J, Renda G, Horowitz J, Granger CB, Wallentin L; ARISTOTLE Investigators. History of Bleeding and Outcomes with Apixaban versus Warfarin in Patients with Atrial Fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial. *J Am Heart Assoc* 2016;175:175-183 (PMID:27179738).
175. Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, Roe MT, Harrington RA, **Alexander JH**, White HD, Van de Werf F, Piccini JP, Held C, Aylward PE, Moliterno DJ, Mahaffey KW, Tricoci P. Sudden Cardiac Death after Non-ST-Segment Elevation Acute Myocardial Infarction. *JAMA Cardiol* 2016;1:73-79 (PMID:27437658).
176. Jaspers FJ, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanan F, Xavier D, Husted S, Wallentin L, **Alexander JH**, Granger CB, Verheugt FW. Polypharmacy and Effects of Apixaban versus Warfarin in Patients with Atrial Fibrillation: Post Hoc Analysis of the ARISTOTLE Trial. *BMJ* 2016;353:i2868 (PMID:27306620).
177. Sandhu RK, Ezekowitz J, Andersson U, **Alexander JH**, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L. The 'Obesity Paradox' in Atrial Fibrillation: Observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. *Eur Heart J* 2016;37:2869-2878 (PMID:27071819).

178. Hijazi Z, Hohnloser SH, Andersson U, **Alexander JH**, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes R, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared with Warfarin in Patients with Atrial Fibrillation in Relation to Renal Function Over Time: Insights from the ARISTOTLE Randomized Clinical Trial. *J Am Coll Cardiol* 2016;1:451-1460 (PMID:27438322).
179. Hijazi Z, Oldgren J, Lindbäck J, **Alexander JH**, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The Novel Biomarker-Based ABC (age, biomarkers, clinical history)-Bleeding Risk Score for Patients with Atrial Fibrillation: A Derivation and Validation Study. *Lancet* 2016;387:2302-2311 (PMID:27056738).
180. Hijazi Z, Lindbäck J, **Alexander JH**, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) Stroke Risk Score: a Biomarker-Based Risk Score for Predicting Stroke in Atrial Fibrillation. *Eur Heart J* 2016;37:1582-1590 (PMID:26920728).
181. **Alexander JH**, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L. Apixaban 5mg Twice Daily and Clinical Outcomes in Patients with Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. *JAMA Cardiol* 2016;1:673681 (PMID:27463942).
182. Prates PR, Williams JB, Mehta RH, Stevens SR, Thomas L, Smith PK, Newby LK, Kalil RA, **Alexander JH**, Lopes RD. Clopidogrel Use after Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. *Braz J Cardiovasc Surg* 2016;31:106-114 (PMID:27556308).
183. Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, **Alexander JH**, Adkinson NF, Levinson AL; REGULATE-PCI Investigators. Pre-Existing Anti-PEG Antibodies are Associated with Severe Immediate Allergic Reactions to Pegnivacogin, a PEGylated Aptamer. *J Allergy Clin Immunol* 2016;138:1712-1715 (PMID:27522158).
184. Gibson CM, Korjian S, Tricoci P, Daaboul Y, **Alexander JH**, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D'Andrea D, Merkely B, Zarebinski M, Ophius TO, Harrington RA. Rationale and design of Apo-1 Event Reduction in Ischemic Syndromes 1 (AEGIS-1): A Phase 2b, Randomized, Placebo-Controlled, Dose-Ranging Trial to Investigate the Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human ApoA-1, after Acute Myocardial Infarction. *J Am Heart Assoc* 2016;180:22-28g (PMID:27659879).
185. Domanski M, Farkouh ME, Zak V, French J, **Alexander JH**, Bochenek A, Hamon M, Mahaffey K, Puskas J, Smith P, Shrader P, Fuster V. Relation of Post-Coronary Artery Bypass Graft Creatine Kinase-MB Elevations and New Q Waves with Long-Term Cardiovascular Death in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease. *Am J Cardiol* 2016;118:1665-1660 (PMID:27816118).
186. Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F,

- Goto S, **Alexander JH**, Wallentin L, Granger CB. Non-major Bleeding with Apixaban vs Warfarin in Patients with Atrial Fibrillation. *J Am Heart Assoc* 2017;103:623-628 (PMID:27798052).
187. Capoulade R, Zeng X, Overbey JR, Ailawadi G, **Alexander JH**, Ascheim D, Bowdish M, Gelijns AC, Grayburn P, Kron IL, Levine RA, Mack MJ, Melnitchouk S, Michler RE, Mullen JC, O’Gara P, Parides MK, Smith P, Voisine P, Hung J. Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation after Ring Annuloplasty. Cardiothoracic Surgical Trials Network (CTSN) Investigators. *Circulation* 2016;134:12471256 (PMID:27777294).
  188. Mehta RH, Van Diepen S, Meza J, Bokesch P, Leimberger JD, Tourt-Uhlig S, Swartz M, Parrotta J, Jankowich R, Hay D, Harrison RW, Fremes S, Goodman SG, Lubner J, Toller W, Heringlake M, Anstrom KJ, Levy JH, Harrington RA, **Alexander JH**; LEVO-CTS Investigators. Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery on Cardiopulmonary Bypass: Rationale and Study Design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) Trial. *J Am Heart Assoc* 2016;182:62-71 (PMID:27914501).
  189. de Souza Brito F, Mehta RH, Lopes RD, Harskamp RE, Lucas BD Jr, Schulte PJ, Tardif JC, **Alexander JH**. Non-Steroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. *Am J Med* 2017;130:462-468 (PMID:27888052).
  190. Gibson CM, Korjian S, Tricoci P, Daaboul Y, Yee M, Jain P, **Alexander JH**, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D’Andrea DM, Deckelbaum LI, Merkely B, Zarebinski M, Oude Ophuis T, Harrington RA. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, after Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). *Circulation* 2016;134:1918-1930 (PMID:27881559).
  191. Browndyke JN, Berger M, Harshbarger TB, Smith PJ, White W, Bisanar TL, **Alexander JH**, Gaca JG, Welsh-Bohmer K, Newman MF, Mathew JP. Resting-State Functional Connectivity and Cognition after Major Cardiac Surgery in Older Adults Without Preoperative Cognitive Impairment: Preliminary Findings. *J Am Geriatr Soc* 2017;65:e6-e12 (PMID:27858963).
  192. Guimarães PO, Wojdyla DM, **Alexander JH**, Thomas L, Alings M, Flaker GC, Al-Khatib SM, Hanna M, Horowitz JD, Wallentin L, Granger CB, Lopes RD. Anticoagulation Therapy and Clinical Outcomes in Patients with Recently Diagnosed Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Int J Cardiol* 2016;227:443-449 (PMID:27852444).
  200. van Diepen S, Merrill PD, Carrier M, Tardif JC, Podgoreanu M, **Alexander JH**, Lopes RD. J Thromb Thrombolysis. Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. *Journal of Thrombosis and Thrombolysis* 2017;43:446-453 (PMID:28194628).
  201. Hess PL, Healey JS, Granger CB, Connolly SJ, Ziegler PD, **Alexander JH**, Kowey PR, Ruff CT, Flaker G, Halperin JL, Hart RG, Lopes RD. The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. *JAMA Cardiol* 2017;2:324-331 (PMID:28097334).
  202. Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, **Alexander JH**, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS. Efficacy and Safety of Apixaban Compared With

- Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. *J Am Heart Assoc* 2017;6 (PMID:28096100).
203. Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Froles S, Duncan A, Soltesz EG, Lubner J, Park S, Argenziano M, Murphy E, Marcel R, Kalavrouziotis D, Nagpal D, Bozinovski J, Toller W, Heringlake M, Goodman SG, Levy JH, Harrington RA, Anstrom KJ, **Alexander JH** for the LEVO-CTS Investigators. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. *N Engl J Med* 2017;5:2032-2042 (PMID:28316276).
204. Westenbrink BD, Alings M, Granger CB, **Alexander JH**, Lopes RD, Hylek EM, Thomas L, Wojdyla DM, Hanna M, Keltai M, Steg PG, De Caterina R, Wallentin L, van Gilst WH. Anemia is Associated with Bleeding and Mortality, but Not Stroke, in Patients with Atrial Fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *J Am Heart Assoc* 2017;185:140-149 (PMID:28267467).
205. Oldgren J, Hjazzi Z, Lindback J, **Alexander JH**, Connolly SJ, Elkelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. *Circulation* 2016;134:1697-1707 (PMID:27569438).
206. Guimarães PO, Lopes RD, Wojdyla DM, Abdul-Rahim AH, Connolly SJ, Flaker GC, Wang J, Hanna M, Granger CB, Wallentin L, Lees KR, **Alexander JH**, McMurray JJV. Effect of Apixaban on All-Cause Death in Patients With Atrial Fibrillation: A Meta-Analysis Based on Imputed Placebo Effect. *Cardiovasc Drugs Ther* 2017;31:295-301 (PMID:28516318).
207. Hess CN, Clare RM, Neely ML, Tricoci P, Mahaffey KW, James SK, **Alexander JH**, Held C, Lopes RD, Fox KAA, White HD, Wallentin L, Armstrong PW, Harrington RA, Ohman EM, Roe MT. Differential Occurrence, Profile, and Impact of First Recurrent Cardiovascular Events After An Acute Coronary Syndrome. *J Am Heart Assoc* 2017;5:194-203 (PMID:28454804).
208. Guimarães PO, Lopes RD, Stevens SR, Zimmerman A, Wruck L, James SK, Haque G, Giraldez RRCV, **Alexander JH**, Alexander KP. Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. *J Am Heart Assoc* 2017;6 (PMID:28438739).
209. Newman JH, Rich S, Abman SH, **Alexander JH**, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. *Am J Respir Crit Care Med* 2017;15:1661-1670 (PMID:28430547).
210. Koshizaka M, Lopes RD, Newby LK, Clare RM, Schulte PJ, Tricoci P, Mahaffey KW, Ogawa H, Moliterno DJ, Giugliano RP, Huber K, James S, Harrington RA, **Alexander JH**. Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. *Am J Med* 2017;130:1170-1176 (PMID:28396226).

211. Lopes RD, Guimarães PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de Barros E Silva P, **Alexander JH**, Granger CB, Diener HC. Intracranial Hemorrhage in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy. *Blood* 2017;129:2980-2987 (PMID:28356246).
212. Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, **Alexander JH**, Wallentin L, Granger CB, Mark DB. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. *JAMA Cardiol* 2017;2:525-534 (PMID:28355434).
213. Ailawadi G, Chang HL, O'Gara PT, O'Sullivan K, Woo YJ, DeRose JJ Jr, Parides MK, Thourani VH, Robichaud S, Gillinov AM, Taddei-Peters WC, Miller MA, Perrault LP, Smith RL, Goldsmith L, Horvath KA, Doud K, Baio K, Gelijns AC, Moskowitz AJ, Bagiella E, **Alexander JH**, Iribarne A. Pneumonia After Cardiac Surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. *J Thorac Cardiovasc Surg* 2017;153:1384-1391 (PMID:28341473).
214. Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Femes S, Duncan A, Soltesz EG, Lubner J, Park S, Argenziano M, Murphy E, Marcel R, Kalavrouziotis D, Nagpal D, Bozinovski J, Toller W, Heringlake M, Goodman SG, Levy JH, Harrington RA, Anstrom KJ, **Alexander JH**; LEVO-CTS Investigators. Levosimendan in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery. *N Engl J Med* 2017; 25:2032-2042 (PMID:28316276).
215. Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindbäck J, Granger CB, **Alexander JH**, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. *J Am Heart Assoc* 2017;6:pil:e004851 (PMID:28645934).
216. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, **Alexander JH**, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. *Am J Med* 2017;23:6 (PMID:28516318).
217. Manning MW, Cooter M, Mathew J, **Alexander JH**, Peterson E, Ferguson TB Jr, Lopes R, Podgoreanu M. Angiotensin Receptor Blockade Improves Cardiac surgical Outcomes in Patients With Metabolic Syndrome. *Ann Thorac Surg* 2017;104:98-105 (PMID: 28131423).
218. Browndyke JN, Berger M, Smith PJ, Harshbarger TB, Monge ZA, Panchal V, Bisanar TL, Glower DD, **Alexander JH**, Cabeza R, Welsh-Bohmer K, Newman MF, Mathew JP, Duke Neurologic Outcomes Research Group (NORG). *Hum Brain Mapp* 2018;39:985-1003 (PMID: 29164774).
219. Rao MP, Vinereanu D, Wojdyla DM, **Alexander JH**, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. *Am J Med* 2018;131:269-275 (PMID:29122636).
220. Mehta RH, **Alexander JH**. LEVO-CTS Steering Committee Members and Trial Investigators. Levosimendan in Cardiac Surgery. *N Engl J Med* 2017;377:1900-1 (PMID:29120128).
221. Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D,



- Wallentin L, Granger CB, **Alexander JH**. Echocardiographic Risk Factors for Stroke and Outcomes in Patients with Atrial Fibrillation Anticoagulated with Apixaban or Warfarin. *Stroke* 2017;48:3266-3273 (PMID:29089455).
222. Hijaz Z, Oldgren J, Lindback J, **Alexander JH**, Connolly SJ, Elkelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L. A Biomarkerbased Risk Score to Predict Death in Patients with Atrial Fibrillation: The ABC (Age, Biomarkers, Clinical History) Death Risk Score. *Eur Heart J* 2018;39:477-485 (PMID:29069359).
223. Gaudino M, **Alexander JH**, Bakaeen FG, Ballman K, Barili F, Calafiore AM, Davierwala P, Goldman S, Kappetein P, Lorusso R, Mylotte D, Pagano D, Ruel M, Schwann T, Suma H, Taggart DP, Tranbaugh RF, Fremes S. Randomized Comparison of the Clinical Outcome of Single versus Multiple Arterial Grafts: The ROMA Trial-Rationale and Study Protocol. *Eur J Cardiothorac Surg* 2017;52:1031-1040 (PMID:29059371).
224. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, **Alexander JH**, Lopes RD. Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. *Am J Med* 2017;130:1440-1448 (PMID:28739198).
225. Gulack BC, Kirkwood KA, Shi W, Smith PK, **Alexander JH**, Burks SG, Gelijins AC, Thourani VH, Bell D, Greenberg A, Goldfarb SD, Mayer ML, Bowdish ME, Cardiothoracic Surgical Trials Network (CTSN). Secondary Surgical-site Infection after Coronary Artery Bypass Grafting: A Multi-institutional Prospective Cohort Study. *J Thorac Cardiovasc Surg* 2018;155:1555-1562 (PMID:29221750).
226. **Alexander JH**, Corrigan-Curay J, McClellan M. The Clinical Trials Transformation Initiative: Looking back, look forward. *Clin Trials* 2018;Suppl:3-4 (PMID:29452518).
227. Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, Verheugt FWA, Vinereanu D, Bahit MC, Halvorsen S, Huber K, Parkhomenko A, Granger CB, Lopes RD, **Alexander JH**. Percutaneous Coronary Intervention and Antiplatelet Therapy in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin: Insights from the ARISTOTLE Trial. *J Am Heart Assoc* 2018;197:133-141 (PMID:29447773).
228. Sherwood MW, Lopes RD, Sun JL, Liaw D, Harrington RA, Wallentin L, Laskowitz DT, James SK, Goodman SG, Darius H, Lewis BS, Gibson CM, Pieper KS, **Alexander JH**. Apixaban Following Acute Coronary Syndromes in Patients with Prior Stroke: Insights from the APPRAISE-2 Trial. *J Am Heart Assoc* 2018;197:1-8 (PMID:29447769).
229. Pol T, Held C, Westerbergh J, Lindbäck J, **Alexander JH**, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z. Dyslipidemia and Risk of Cardiovascular Events in Patients with Atrial Fibrillation Treated with Oral Anticoagulation Therapy: Insights from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. *J Am Heart Assoc* 2018;1:7-3 (PMID:29419390).
230. Chiarito M, Cao D, Cannata F, Godino C, Lodigiani C, Ferrante G, Lopes RD, **Alexander JH**, Reimers B, Condorelli G, Stefanini GG. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: A Systematic Review and Meta-analysis. *JAMA Cardiol* 2018;3:234-241 (PMID:29417147).

231. Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola VP, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, **Alexander JH**. Antithrombotic Therapy Use and Clinical Outcomes Following Thromboembolic Events in Patients with Atrial Fibrillation: Insights from ARISTOTLE. *Eur Heart J Cardiovasc Pharmacother* 2018;4:75-81 (PMID: 29385429).
232. Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, Gersh BJ, Avezum A, Hanna M, Held C, Wallentin L, Granger CB, **Alexander JH**. Outcomes in Anticoagulated Patients with Atrial Fibrillation and with Mitral or Aortic Valve Disease. *Heart* 2018;104:1292-1299 (PMID:29352007).
233. Rosenstock J, Perkovic V, **Alexander JH**, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, Eynatten MV, McGuire DK, CARMELINA Investigators. Rationale, Design and Baseline Characteristics of the Cardiovascular Safety and Renal Microvascular Outcome Study with LINagliptin (CARMELINA): A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients with Type 2 Diabetes and High Cardio-renal Risk. *Cardiovasc Diabetol* 2018;17:39 (PMID:29540217).
234. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, DM Wojdyla, Ridefelt P, Lawrence J, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser S, **Alexander JH**, Granger CB, Wallentin L for the ARISTOTLE Committees and Investigators. Digoxin and Mortality in Patients with Atrial Fibrillation. *J Am Coll Cardiol* 2018;71:10631074 (PMID: 29519345).
235. Wang A, Wu A, Wojdyla D, Lopes RD, Newby LK, Newman MF, Smith PK, **Alexander JH**. Dual Antiplatelet Therapy for Perioperative Myocardial Infarction Following CABG Surgery. *Am Heart J* 2018;199:150-155 (PMID:29754654).
236. Fanaroff AC, Steffel J, **Alexander JH**, Lip GYH, Califf RM, Lopes RD. Stroke Prevention in Atrial Fibrillation: Re-defining “Real-World Data” within the Broader Data Universe. *Eur Heart J* 2018;39:2932-2941 (PMID:29688403).
237. Berwanger O, de Barros E Silva PGM, Dall Orto FTC, de Andrade PB, de Castro Bienert IR, Bosso CE, Mangione J, Polanczyk CA, Sousa A, Kalil R, de Moura Santos L, Sposito AC, Rech RL, Sousa ACS, Baldissera F, Nascimento BR, de Andrade Jesuino I, Santucci EV, Damiani LP, Laranjeira LN, Borges de Oliveira JA, Giraldez RR, Cavalcanti AB, Pereira SB, Mattos LA, Armaganijan LV, Guimarães HP, Sousa JE, **Alexander JH**, Granger CB, Lopes RD. Rationale and Design of the Statins Evaluation in Coronary Procedures and Revascularization: The SECURE-PCI Trial. *Am Heart J* 2018;198:129134 (PMID:29653634).
238. Gurbel PA, Tantry US, D'Andrea D, Chung T, **Alexander JH**, Bliden KP, Wright SD, Tricoci P. Evaluation of Potential Antiplatelet Effects of CSL112 (Apolipoprotein A-I (Human)) in Patients with Atherosclerosis: results from a phase 2a study. *J Thromb Thrombolysis* 2018;45:469-476 (PMID:29582212).
239. Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, **Alexander JH**, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. The Use of Biomarkers to Predict Specific Causes of Death in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Circulation* 2018;138:1666-1676 (PMID:29871978).
240. Inohara T, Pieper K, Wojdyla DM, Patel MR, Jones WS, Tricoci P, Mahaffey KW, James SK, **Alexander JH**, Lopes RD, Wallentin L, Ohman EM, Roe MT, Vemulapalli S.

- Incidence, Timing, and Type of First and Recurrent Ischemic Events in Patients with and without Peripheral Artery Disease after an Acute Coronary Syndrome. *Am Heart J* 2018;201:25-32 (PMID:29910052).
241. Carson JL, Stanworth SJ, **Alexander JH**, Roubinian N, Fergusson DA, Triulzi DJ, Goodman SG, Rao SV, Doree C, Hebert PC. Clinical Trials Evaluating Red Blood Cell Transfusion Thresholds: An Updated Systematic Review and with Additional Focus on Patients with Cardiovascular Disease. *Am Heart J* 2018;200:96-101 (PMID:29898855).
  242. Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, Mehran R, Windecker S, **Alexander JH**. An Open-Label, 2x2 Factorial, Randomized Controlled Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention: Rationale and Design of the AUGUSTUS Trial. *Am Heart J* 2018;200:17-23 (PMID:29899884).
  243. Lopes RD, de Barros E Silva PGM, de Andrade Jesuino I, Santucci EV, Barbosa LM, Damiani LP, Nakagawa Santos RH, Laranjeira LN, Dall Orto FTC, Beraldo de Andrade P, de Castro Bienert IR, **Alexander JH**, Granger CB, Berwanger O. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights from the SECURE-PCI Randomized Clinical Trial. *JAMA Cardiol* 2018;3:1113-1118 (PMID:30264159).
  244. Smith PJ, Browndyke JN, Monge ZA, Harshbarger TB, James ML, Gaca JG, **Alexander JH**, Berger MM, Newman MF, Milano CA, Mathew JP; Neurologic Outcomes Research Group (NORG). Longitudinal Changes in Regional Cerebral Perfusion and Cognition Following Cardiac Surgery *Ann Thorac Surg.* 2018;4975:31301-31308 (PMID:30253158).
  245. Fellin LC, Callaghan JEM, **Alexander JH**, Harrison-Breed C, Mavrou S, Papatthanasiou M. Empowering Young People Who Experienced Domestic Violence and Abuse: The Development of a Group Therapy Intervention. *Clin Child Psychol Psychiatry* 2018 Aug 29. [Epub ahead of print] (PMID:30156129).
  246. Minter S, Armour A, Tinnemore A, Strub K, Crowley AL, Bloomfield GS, **Alexander JH**, Douglas PS, Kisslo JA, Velazquez EJ, Samad Z. Crowdsourcing Consensus: Proposal of a Novel Method for Assessing Accuracy in Echocardiography Interpretation. *Int J Cardiovasc Imaging* 2018;34:1725-1730 (PMID: 30128849).
  247. Horowitz JD, De Caterina R, Heresztyn T, **Alexander JH**, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L; ARISTOTLE Investigators. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. *J Am Coll Cardiol* 2018;14:72:721733 (PMID:30092948).
  248. Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, **Alexander JH**, Kisslo JA, Wang A, Mark DB, Velazquez EJ. Long-term outcomes of mitral regurgitation by type and severity. *Am Heart J* 2018;203:39-48 (PMID:30015067).
  249. Berwanger O, Santucci EV, de Barros E Silva PGM, Jesuino IA, Damiani LP, Barbosa LM, Santos RHN, Laranjeira LN, Egydio FM, Borges de Oliveira JA, Dall Orto FTC, Beraldo de Andrade P, Bienert IRC, Bosso CE, Mangione JA, Polanczyk CA, Sousa AGMR, Kalil RAK, Santos LM, Sposito AC, Rech RL, Sousa ACS, Baldissera F, Nascimento BR, Giraldez RRCV, Cavalcanti AB, Pereira SB, Mattos LA, Armaganijan LV, Guimarães HP, Sousa JEMR, **Alexander JH**, Granger CB, Lopes RD; SECURE-PCI Investigators. Effect

- of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. *JAMA* 2018;319:1331-1340 (PMID:29525821).
250. Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, **Alexander JH**, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L. Obesity Paradox on Outcome in Atrial Fibrillation Maintained even Considering the Prognostic Influence of Biomarkers: insights from the ARISTOTLE Trial. *Open Heart* 2018;5:e000908 (PMID:30487982).
  251. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, **Alexander JH**, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *JAMA* 2018 Nov 9. doi: 10.1001/jama.2018.18269. [Epub ahead of print] (PMID:30418475).
  252. Gibson CM, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, Tricoci P, **Alexander JH**, Kastelein JJP, Mehran R, Bode C, Lewis BS, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo DJ, Duerschmied D, Ophuis TO, Merkely B. Non-refereed publications: The CSL112-2001 Trial: Safety and Tolerability of Multiple Doses of CSL112 (apolipoprotein A-I [human]), an Intravenous Formulation of Plasma-derived Apolipoprotein A-I, Among Subjects with Moderate Renal Impairment after Acute Myocardial Infarction. *Am Heart J* 2018;208:81-90 (PMID:30580130).
  253. Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, **Alexander JH**, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of Apixaban vs Warfarin in Patients with Atrial Fibrillation and Multi-morbidity: Insights from the ARISTOTLE Trial. *Am Heart J* 2018 Nov 22. pii: S0002-8703(18)30296-5. doi: 10.1016/j.ahj.2018.09.017 [Epub ahead of print] (PMID:30579505).
  254. Ranney DN, Williams JB, Mulder H, Wojdyla D, Cox ML, Gibson CM, Mack MJ, Daneshmand MA, **Alexander JH**, Lopes RD. Comparison of Outcomes and Frequency of Graft Failure With Use of Free Vs In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial). *Am J Cardiol* 2018 Nov 24. pii: S0002-9149(18)32110-6. doi: 10.1016/j.amjcard.2018.11.029 [Epub ahead of print] (PMID:30538035).
  255. McGuire DK, **Alexander JH**, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra DS, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. *Circulation* 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.038352 [Epub ahead of print] (PMID:30586723).
  256. Fanaroff AC, Clare R, Pieper KS, Mahaffey KW, Melloni C, Green J, **Alexander JH**, Jones WS, Harrison RW, Mehta RH, Povsic TJ, Moreira HG, Al-Khatib SM, Roe MT, Kong DF, Mathews R, Tricoci P, Holman RR, Wallentin L, Held C, Califf RM, Alexander KP, Lopes RD. Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in

Cardiometabolic Clinical Trials: A Pooled Analysis of 9,259 Deaths in 9 Trials. *Circulation* 2018 Nov 28. doi: 10.1161/CIRCULATIONAHA.118.037202 [Epub ahead of print] (PMID:30586739).

**Non-refereed publications:**

1. **Alexander JH**, Alexander KP, Kong DF, Tung CY, Whellan DJ. Session highlights from the American Heart Association meetings: November 9-12, 1997. *J Am Heart Assoc* 1998;135:157-180 (PMID:9453536).
2. **Alexander JH**, Greenbaum, AB, Hudson MP, Kong DF, Miller JM, Tung CY, Whellan DJ. Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. *Am Heart J* 1998;135:1099-1114 (PMID:9630118). **Alexander JH**, Kong, D. Session highlights from the European Society of Cardiology XXth Annual Congress: August 22 to 26, 1998. *J Am Heart Assoc* 1999;137:180-186 (PMID:9878951).
3. **Alexander JH**, Kong DF, Cantor WJ. Highlights from the 71st American Heart Association Scientific Sessions: November 8 to 11, 1998. *J Am Heart Assoc* 1999;137:555-574 (PMID:10047641).
4. **Alexander JH**, Al-Khatib SM, Cantor W, Greenbaum, AB, Hudson MP, Kong DE, Shah M. Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999. *J Am Heart Assoc* 1999;138:175-190 (PMID:10385783).
5. McGuire DK, Hudson MP, East MA, Dyke CK, Battle J, Bahit MC, Al-Khatib SM, **Alexander JH**. Highlights from the American Heart Association 72nd Scientific Sessions: November 6 to 10, 1999. *J Am Heart Assoc* 2000;139:359-370.
6. Callahan KP, Malinin AI, Gurbel PA, **Alexander JH**, Granger CB, Serebruany VL. Platelet Function and Fibrinolytic Agents: Two Sides of a Coin? *Cardiology* 2001;95:55-60 (PMID:11423707).
7. **Alexander JH**, Peterson ED, Chen AY, Harding TM, Adams DB, Kisslo J. Training and Accuracy of Non-cardiologists in Simple Use of Point-of-care Echo: A Preliminary Report from the Duke Limited Echo Assessment Project (LEAP). *The Thoraxcentre Journal* 2001;13:105-110. **Alexander JH**, Harrington RA. Advances in Antithrombotic Therapy in Acute Myocardial Infarction: ExTRACT-TIMI 25 and OASIS 6. *Clinical Trials Report. Curr Cardiol Rep* 2006;8:279-281 (PMID:16883666).
8. Harrington RA, **Alexander JH**, Eds. Management of Acute Coronary Syndromes section. *Curr Cardiol Rep* 2006;8:279-306.
9. Hodgson PK, **Alexander JH**, Harrington RA. Introduction of International Research Facilities. The Duke Clinical Research Institute. *International Review Thrombosis* 2007;2:4251.
10. Lopes RD, **Alexander JH**. Thrombosis in the Field of Cardiology. *International Review of Thrombosis* 2008;3:45-54.
11. **Alexander JH**. The Current State of Antiplatelet Therapy in Acute Coronary Syndromes: The Data and the Real World. Platelet Response in Acute Coronary Syndromes. *Cleveland Clinic Journal of Medicine* 2009;Suppl 1;76:S16-S23 (PMID:19332589).
12. Lopes RD, Garcia D, Becker RC, Granger CB, Newby LK, **Alexander JH**, Jolicoeur EM, Handler A, Pieper KS, Carvalho AC, Guimaraes HP, Chamone DAF, Baruzzi AC, Machado FS, Timmerman A, Lopes AC. Highlights from the II International Symposium of Thrombosis

- and Anticoagulation (STA), October 22-23, 2009, Sao Paulo, Brazil. *J Thromb Thrombolysis* 2010;29:395-408 (PMID:20157840).
13. Lopes RD, Becker RC, **Alexander JH**, Armstrong PW, Califf RM, Chan MY, Crowther M, Granger CB, Harrington RA, Hylek EM, James SK, Jolicoeur EM, Mahaffey KW, Newby LK, Peterson ED, Pieper KS, Van de Werf F, Wallentin L, White HD, Carvalho AC, Giraldez RB, Guimaraes HP, Nader HB, Kalil RAK, Bizzachi JMA, Lopes AC, Garcia DA. Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, Sao Paulo, Brazil. *J Thromb Thrombolysis* 2011;32:242-266 (PMID: 21547405). Wiggins NB, Granger CB, **Alexander JH**. Novel Oral Anticoagulants after Acute Coronary Syndromes. *Cardiovasc Drugs Ther* 2012;26:265-71 (PMID: 22434545).
  14. Vavalle JP, **Alexander JH**. Authors' reply to 'The Not so 'Ideal' Body Weight-Based Dosing of Integrilin in Obesity.' *Am Heart J* 2012;163:e25 (PMID: 22520550).
  15. **Alexander JH**. Factor Xa Inhibitors. In: Moliterno D, Dehmer GJ, Kandzari DE, Rao SV, Ziada KM, eds. *CathSAP 4. Cardiac Catheterization and Interventional Cardiology Self-Assessment Program*. 4th version. Washington, DC: American College of Cardiology Foundation; 2013. <http://www.cardiosource.org/Lifelong-Learning-and-MOC/CertifiedLearning/SAPs/2012/CathSAP-4.aspx>. Accessed February 26, 2013.
  16. Sherwood MW, **Alexander JH**. Transitions with Novel Oral Anticoagulants. <http://anticoagulation.cardiosource.org>. November 20, 2013. <http://anticoagulation.cardiosource.org/Hot-Topics/2013/11/Transitions-With-Novel-OralAnticoagulants.aspx>. Accessed December 3, 2013.
  17. Harskamp RE, Schulte PJ, **Alexander JH**, Lopes RD. Authors' reply to 'Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes after Coronary Artery Bypass Surgery'. *Ann Thorac Surg* 2014;98:1890 (PMID:25441825).
  18. Kertai, M D, Li, Y-J, Li, Y-W, Ji, Y, **Alexander, JH**, Newman, MF, Podgoreanu, MV. Genome-wide Association Study of Perioperative Myocardial Infarction after Coronary Artery Bypass Surgery. *BMJ Open* 2015;5:e006920 (PMID:25948407).
  19. Roe MT, Mahaffey KW, Ezekowitz JA, **Alexander JH**, Goodman SG, Hernandez A, Temple T, Berdan L, Califf RM, Harrington RA, Peterson ED, Armstrong PW. The Future of Cardiovascular Clinical Research in North America and Beyond—addressing Challenges and Leveraging Opportunities through Unique Academic and Grassroots Collaborations. *J Am Heart Assoc* 2015;169:743-750 (PMID:26027610).
  20. Hess CN, Lopes RD, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack MJ, Kouchoukos NT, Peterson ED, **Alexander JH**. Response to Letters Regarding Article, Saphenous Vein Graft Failure after Coronary Artery Bypass Surgery: Insights from PREVENT IV". *Circulation* 2015;132:e29 (PMID:26216091).
  21. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, Lopes RD, **Alexander JH**, Mathew JP, Velazquez EJ, Milano CA, Smith PK. Response to letter regarding Article, "Surgical Revascularization Is Associated with Maximal Survival in Patients with Ischemic Mitral Regurgitation: A 20-year Experience". *Circulation* 2015;131:e378-9 (PMID:25779550).
  22. Lincoff AM, **Alexander JH**, Mehran R. REGULATE-PCI trial--Author's reply. *Lancet* 2016;387:1500-1501 (PMID:27115975).
  23. Harskamp RE, **Alexander JH**, Ferguson TB, Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith

PK, Lopes RD. Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". *Circulation* 2016;133:1987-1988 (PMID:27217439).

24. Vora AN, **Alexander JH**, Lopes RD. Dabigatran Compared with Rivaroxaban vs Warfarin. *JAMA Intern Med.* 2017;742-743 (PMID:28460098).

#### **Chapters in books:**

1. Harrington RA, **Alexander JH**. Peptide and Non-Peptide Inhibitors of Platelet Glycoprotein IIb/IIIa, Chapter 9. In: *Antiplatelet Therapy in Clinical Practice*. Ferguson, Chronos N, Harrington RA, eds. Martin Dunitz Ltd, London, 2000.
2. **Alexander JH**, Steinhubl SR. Aspirin resistance, Chapter 18. In: *Acute Coronary Syndromes*, Ed. Topol EJ. Marcel Dekker, Inc., New York, 2000.
3. Tricoci P, **Alexander JH**, Harrington RA. Pentasaccharide and Other Factor Xa Inhibitors, Chapter 8 (123–144). In: *Therapeutic Strategies in Thrombosis*. Eds. Kristensen SD, De Caterina R, Moliterno DJ. Clinical Publishing, Oxford, United Kingdom, 2005.
4. Gutierrez A, Tricoci P, **Alexander JH**. Pentasaccharide Derivatives, Chapter 9 (128–149). In: *Therapeutic Advances in Thrombosis*, 2nd ed. Eds. Moliterno DJ, Kristensen SD, De Caterina R. Wiley-Blackwell, Hoboken, NJ, 2012.
5. Vavalle JP, **Alexander JH**, Roe MT. Acute Coronary Syndromes: Manifestations and Management, Chapter 90 (1064–1086). In: *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*, 6th ed. Eds. Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, Colman RW. Lippincott Williams & Wilkins, Philadelphia, PA, 2012.

**Books:** None

#### **Non-authored publications:**

1. Dolor RJ, Ruybalid RL, Uyeda L, Edson RG, Phibbs C, Vertrees JE, Shih MC, Jacobson AK, and Matchar DB for the THINRS Site Investigators. An Evaluation of Patient Self-Testing Competency of Prothrombin Time for Managing Anticoagulation: Pre-randomization Results of VA Cooperative Study #481 – The Home INR Study (THINRS). *J Thromb Thrombolysis* 2010;30:263-275 (PMID:20628787). (acknowledgement as Clinical Endpoints Committee reviewer)
2. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P and the THINRS Executive Committee and Site Investigators. Effect of Home Testing of International Normalized Ratio on Clinical Events. *N Engl J Med* 2010;363:1608-1620 (PMID:20961244). (acknowledgement as Clinical Endpoints Committee reviewer)

#### **Published scientific reviews:**

1. **Alexander JH**, Dyke C. Virtual Patient: Acute Coronary Syndrome Overview. CD-ROM. South San Francisco, CA: COR Therapeutics, Inc., 1999.

#### **Editorials, position, and background papers:**

1. **Alexander JH**, Harrington RA. Adjunctive Antiplatelet Therapy in Acute Myocardial Infarction: The Road to Improved Infarct-related Artery Patency. *J Thromb Thrombolysis* 1997;4:353-355 (PMID:10639641).
2. **Alexander JH**, Patel MR. Screening for Structural Heart Disease: Time to Stop Listening and Start Looking. *Am Heart J* 2003;146:570-571 (PMID:14564308).
3. **Alexander JH**. Clinical Trials in Japan and the United States. *Am Heart J* 2004;147:200-201 (PMID:14760313).
4. Becker RC, **Alexander JH**, Li YF, Bovill E, Spencer FA, Robertson TL, Kunitada S, Dyke CK, Harrington RA. Combined Coagulation Phase-directed Factor Xa Inhibition with Heparin Compounds and DX-9065a—A Direct and Selective Antagonist. *Thromb Haemost* 2004;92:1229-1231 (PMID:15622616).
5. **Alexander JH**, Harrington RA, Ferguson TB, Peterson ED, Gibson CM, Kouchoukos NT; for the PREVENT IV Investigators. Efficacy and Safety of Edifoligide—Reply. *JAMA* 2006;295:1514-1515 (PMID:16595752).
6. Harrington RA, **Alexander JH**, Hochman JS, Reynolds HR, Dzavik V, Van de Werf FJ. Tissue plasminogen activator in Patients with Acute Myocardial Infarction and Cardiogenic Shock—Reply. *JAMA* 2007;298:972-973 (PMID:17785640).
7. **Alexander JH**, Ellis SJ, Tardif JC. Clopidogrel Treatment and the MEND-CABG II Trial—Reply. *JAMA* 2008;300:1021-1022 (PMID:18768409).
8. Lopes RD, **Alexander JH**, Ferguson TB. Endoscopic versus Open Vein-Graft Harvesting—Reply. *N Engl J Med* 2009;361:1907-1910 (PMID:19911452 and 19890137).
9. **Alexander JH**. Clinical-Outcome Trials in Cardiac Surgery — Have We Primed the Pump? *N Engl J Med* 2013;368:1247-1248 (PMID:23534564).
10. **Alexander JH**. Off-pump or on-pump Coronary-artery Bypass Grafting. *N Engl J Med* 2013;369:397 (PMID:23847789).
11. Harskamp RE, Bonatti JO, Zhao DX, Puskas JD, de Winter RJ, **Alexander JH**, Halkos ME. Standardizing Definitions for Hybrid Coronary Revascularization. *J Thorac Cardiovasc Surg* 2014;147:556-560 (PMID:24280716).
12. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, **Alexander JH**, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanus F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Response to letter regarding article "Efficacy and Safety of Apixaban Compared with Warfarin At Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation." *Circulation* 2014;129:e21-2 (PMID:24421367).
13. **Alexander JH**, Thomas LE. Using Data to Guide Anticoagulation in Patients with Atrial Fibrillation: Does the Analysis Fit the Question? *JAMA Cardiol* 2016:121-122 (PMID:27437881).
14. **Alexander JH**. Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes? *JAMA* 2018;319:1661-1662 (PMID:29710146).

**Reviewer and editorial boards:**

American Heart Journal, Reviewer  
Associate Editor (2001–2007)



Editorial Board (2007–present)  
 Journal of Thrombosis and Thrombolysis, Reviewer  
 Editorial Board (2001–2010)  
 Journal of Electrocardiography, Reviewer American Journal of Cardiology,  
 Reviewer Laboratory and Clinical Medicine, Reviewer  
 Circulation, Reviewer  
 Journal of the American College of Cardiology, Reviewer  
 Clinical Trials Section Editor (2014–present)  
 Archives of Internal Medicine, Reviewer  
 JAMA, Reviewer  
 The Lancet, Reviewer  
 The Medical Letter, Reviewer  
 Annals of Internal Medicine, Reviewer  
 European Heart Journal, Reviewer  
 New England Journal of Medicine, Reviewer  
 German Federal Ministry of Education and Research, Clinical Trial Grant Reviewer  
 Blood, Reviewer  
 JAMA Cardiology, Reviewer JAMA  
 Internal Medicine, Reviewer  
 Thrombosis Journal, Reviewer

**Professional awards and special recognitions:**

Chief Fellow, Duke Clinical Research Institute	1998–1999
Clinical Site Coordination Award, Duke Cardiology Research	2000
Visiting Scholar, National Cardiovascular Center, Osaka Japan	2005
Japan Foundation for Aging and Health, Program for the Invitation of Foreign Scientists to Japanese Institutions	
DCRI Robert M. Califf Award for Outstanding Mentorship	2009
Visiting Professor, Chiba University, Chiba Japan	2012–present

**Organizations and participation:**

**DUMC / DCRI academic and administrative activities:**

Clinical Events Committee, DCRI	1996–present
CRF Standardization Initiative, DCRI	1997–1999
Ethics Committee, Duke Hospital	1996–2007
Co-Chair, Clinical Ethics Service	1999–2005
Curriculum Sub-committee, Medical Humanities Bioethics and Law, Duke Medical School	2001–2003
Refusal of Transfusion of Blood and Blood Products Policy Committee, Duke Hospital	2002–2003
DCRI Cardiology Site-Based Research Board	2003–2005
Division of CVM Strategic Initiative, Team Leader	2004
DCRI, Faculty/Operations Interface Team	2003–2005

Electrophysiology Section Chief Search Committee, Chair,	2005–2007
Duke Cardiovascular Fellows Society (DUCCS), Board Member	2005–2007
Duke Heart Center Performance Improvement Board, Quality and Safety of Inpatient Services	2006–2014
Duke Heart Center Site-Based Research (SBR), Director	2006–2011
DCRI, Marketing Committee	2007–2009
DCRI, Quota / Portfolio Management Committee	2007–2008
Duke Research Administration Continuous Improvement (RACI) Faculty Advisory Group	2008–2012
Heart Center Executive Leadership Committee	2008–present
Clinical Trial Transformation Initiative (CTTI)	2010–present
DCRI Representative	2010–2014
Clinical Trial Quality By Design Project Executive Committee	2014–2015
Co-Chair	2015–present
Duke Atrial Fibrillation Center, Safety Monitory Board, Chair	2011–2013
Duke LEADER Program Selection Committee	2011–2013
Duke SOM Professionalism Committee, Ad Hoc member	2011
Duke Echocardiography Laboratory / CDU, Interim Director	2018–present
Duke Heart Center IT Committee, Member	2018–present

**National and international professional societies and committee activities:**

Hasting Center	1993–2004
Massachusetts Medical Society	1993–present
American Medical Association	1993–2006
American College of Cardiology	1998–present
Fellow, American College of Cardiology Abstract Reviewer	2002–present
American Heart Association	1998–present
Fellow, American Heart Association	2014–present
Council on Clinical Cardiology	2003–present
Membership and Communications Committee	2003–2005
Samuel A. Levine Award Evaluation Committee	2014–2018
Abstract Reviewer Session Builder	
Heart Ball Gala	2000–2004
American Society of Echocardiography	2000–2006
VA Cooperative Studies Program Scientific Evaluation Committee Acting Chair	2012–present
Chair	2014–2015
International Advisory Group, UK Medical Research Council, Network for Trials Methodology	2015–present
Romanian Society of Cardiology, Honorary Member	2016-present

VA CSP / NCI NAVIGATE Program Review Committee Chair 2018

**Teaching responsibilities:**

**Clinical teaching:**

General Medicine Teaching Attending	2001, 2003
Duke Medicine Intern / Resident Subspecialty Clinic Preceptor	2002–present
Zareen Farukhi, Medical Resident, Cardiology Clinic	2003–2004
James Yau, Medical Resident, Cardiology Clinic	2005–2007
Cheryl Robertson, Medical Resident, Cardiology Clinic	2010–2011
Duke University SOM, Body & Disease, Cardiology Content Expert	2012, 2013, 2014

**Clinical research teaching:**

DCRI Cardiovascular Medicine Fellows	2000–present
Patrick Weston, Medical Student, Clinical Research	2001–2002
Eric Crespo, Medical Resident, Clinical Research	2001–2004
Tarel Patel, Medical Resident, Clinical Research	2001
Artie Hendricks, CES Intern, Clinical Ethics Service	2001
Jeffrey Griffin, Medical Student, Clinical Research	2002–2006
Melissa Calder, College Student, Clinical Research	2003–2004
Gazala Haque, Masters of Health Sciences Examining Committee	2003
Akiko Kada, Clinical Research, ARO Operations	2005
James Yau, Medical Resident, Clinical Research	2005–2007
Renato Lopes, Research Fellow	2007–2009
Jason Katz, Research Fellow	2008–2009
Jennifer Vergara-Jimenez, Research Fellow	2008–2009
Jonathan Piccini, Research Fellow	2008–2011
Judson Williams, CT Surgery Research Resident	2009–2011
John Vavalle, Research Fellow	2010–2012
Masaya Koshizaka, Chiba University Research Fellow	2011–2013
Brian Englum, CT Surgery Research Resident	2012–2014
Alice Wang, CT Surgery Research Resident	2015–2017
Morgan Cox, CT Surgery Research Resident	2017–2019
Oliver Jawitz, CT Surgery Research Resident	2018-2020

Duke, SOM, New Faculty Orientation Panelist – Clinical Research 2011, 2012

**Invited lectures:**

**International:**

1. Conference Director and Speaker. Ethics in Practice and Policy for Japanese-American Clinical Trials. Tokyo, Japan. May 29-30, 2003.

2. Direct Factor Xa Inhibition in Percutaneous Coronary Intervention and Acute Coronary Syndromes: The XaNADU Trials. ISTH Daiichi Symposium. Birmingham, England. July 15, 2003.
3. Global Regulatory Harmonization and Medical Devices Clinical Trials, General Issues in Global Harmonization. Ethical Considerations. Japanese Circulatory Society Meetings. Tokyo, Japan. March 28, 2004.
4. Site Based Research Infrastructure in Japan – The View from the Duke Clinical Research Institute (DCRI). US Harmonization By Doing (HBD) Think Tank. Tokyo, Japan. January 28, 2005.
5. Program Director. Duke / DCRI Japanese Clinical Research Coordinator (CRC) Training Symposium. Tokyo, Japan. January 29, 2005.
6. Advances in Antithrombotic Therapy for Acute Coronary Syndromes. 19th Annual Meeting of the Japanese Coronary Association. Osaka International Convention Center, Osaka, Japan. December 9, 2005.
7. The Principal Investigator in Clinical Research. Symposium on International Harmonization of Clinical Research for Medical Devices. 19th Annual Meeting of the Japanese Coronary Association. Osaka International Convention Center, Osaka, Japan. December 10, 2005.
8. Program Planner and Speaker. Harmonization By Doing (HBD) First Annual Think Tank–East. Overview, Review, Forward View. Tokyo, Japan. December 11-13, 2005
  - a. Language—Communication in Global Clinical Research
  - b. The PseudoMetrics DES Program
  - c. What’s Important to Add Quality and Efficiency and to Reduce Time and Cost in Clinical Trials—Faster, Better, Cheaper
9. Improved Patient Care In Hospitals That Do Research. NPO International TRI Network 1<sup>st</sup> Annual Public Forum on Clinical Research. Yokohama, Japan. December 15, 2005.
10. The Experience of Multinational Study (Japan/US). The Second Multitrack Workshop in Japan. DIA Congress on Moving Toward a New Era in New Drug Evaluation. Drug Information Association, Japan. Tokyo Conference Center, Shinagawa, Tokyo, Japan. April 13, 2006.
11. The Duke Clinical Research Institute (DCRI) and the US/Japan Harmonization by Doing (HBD) Initiative. University of Tokyo, Clinical Research Conference. University of Tokyo, Tokyo, Japan. April 21, 2006.
12. Harmonization by Doing (HBD) and the Infrastructure for Clinical Research. Integrative Celerity Research to Deliver Better Treatment Options Critical Path and Roadmap for Clinical Evaluation of Medical Devices. 20th Annual Meeting of the Japanese Coronary Association. Tokyo, Japan. December 9, 2006.
13. The Duke Clinical Research Institute (DCRI)—Clinical Research Across the Spectrum of Acute Coronary Syndromes. Special Lecture. National Cardiovascular Center, Osaka, Japan. December 11, 2006.
14. Improved Patient Care Through Clinical Research. NPO International TRI Network 2nd Annual Public Forum on Clinical Research. Yokohama, Japan. December 15, 2006.
15. Drug Eluting Stent Thrombosis—Data from Randomized Trials and Registries. Special Session on DES Thrombosis. NPO International TRI Network 2nd Annual Public Forum on Clinical Research. Yokohama, Japan. December 15, 2006.

16. Program Co-Director. Duke-Abbott English Paper Writing Program. Special Session Great Wall Congress 2007. Beijing, China. October 13-14, 2007.
17. Current Status and Future Perspective of Antiplatelet Therapy in the Management of Coronary Artery Disease. Japan Circulation Society 2009. Osaka, Japan. March 22, 2009.
18. Antiplatelet Therapy in Acute Coronary Syndromes in 2009: Moving Beyond Aspirin and Clopidogrel. Japan Circulation Society 2009. Osaka, Japan. March 21, 2009.
19. Japan Circulation Society Global Approach for Challenging Against Cardiovascular Risk—Cardiovascular Care and Research Priorities: A North American Perspective. Japan Circulation Society 2009. Osaka, Japan. March 21, 2009.
20. Thrombosis in Atrial Fibrillation. International Symposium on Thrombosis and Anticoagulation 2009. Sao Paulo, Brazil. October 22, 2009.
21. Globalization of Clinical Research. International Symposium on Thrombosis and Anticoagulation 2009. Sao Paulo, Brazil. October 22, 2009.
22. Biomarkers of Thrombosis. International Symposium on Thrombosis and Anticoagulation 2009. Sao Paulo, Brazil. October 22, 2009.
23. Relative Importance of Stroke versus Bleeding Risks in Patients with Atrial Fibrillation. International Symposium on Thrombosis and Anticoagulation 2010. Sao Paulo, Brazil. October 15, 2010.
24. Anti-thrombotic Therapy: Proximal versus Distal Targets in Acute and Convalescent ACS. New Concepts in Acute Coronary Syndromes: Beyond 2000 (XVI). Montreal, Canada. October 24, 2010.
25. Thromboembolism Prophylaxis in Atrial Fibrillation: Past, Present, and Future. Japan Heart Rhythm Society 2011. Fukuoka, Japan. September 21, 2011.
26. Apixaban versus Warfarin in Patients with Atrial Fibrillation: Results of the ARISTOTLE Trial. New Trends of Antithrombotic Therapy. Asia Pacific Heart Rhythm Society 2011. Fukuoka, Japan. September 21, 2011.
27. Development of New Oral Anticoagulants in Patients with Atrial Fibrillation and Acute Coronary Syndromes: Lessons Learned. Keynote Lecture: Update Treatment in Clotting and Fibrinolytic System Session. Japanese Circulation Society 2012. Fukuoka, Japan. March 16, 2012.
28. Antithrombotic Therapy Post-ACS: Where are we and where are we going? Sponsored Program. Japanese Circulation Society 2012. Fukuoka, Japan. March 17, 2012.
29. Academic Physician Involvement in New Drug Development: Lessons from ARISTOTLE. CCRC 10<sup>th</sup> Anniversary and CFMRC Inauguration Symposium. Chiba University. Chiba, Japan. March 19, 2012.
30. Antithrombotic Therapy Post-Acute Coronary Syndrome. Update on Antithrombotic Therapy in ACS and AF—Duke Symposium. XXVII Congresso Centroamericano y El Caribe de Cardiologia. Panama City, Panama. June 8, 2012.
31. Risk Scores in Clinical Practice: Are they Useful? Update on Antithrombotic Therapy in ACS and AF—Duke Symposium. XXVII Congresso Centroamericano y El Caribe de Cardiologia. Panama City, Panama. June 8, 2012.
32. Oral Anti-Factor Xa Agents: A New Opportunity. Update on Antithrombotics in Acute Coronary Syndromes. European Society of Cardiology Congress, Munich, Germany. August 28, 2012.
33. Cerebrovascular Stroke and Bleeding in Anticoagulated Patients with Atrial Fibrillation:

- Predictors and Consequences. New Frontiers in the Diagnosis and Treatment of Atrial Fibrillation and Acute Coronary Syndrome, Brazilian Society of Cardiology Meetings. Recife, Brazil. September 14, 2012.
34. Interpreting the Results of the Clinical Trials: ATLAS 2 and APPRAISE 2. New Frontiers in the Diagnosis and Treatment of Atrial Fibrillation and Acute Coronary Syndrome. Brazilian Society of Cardiology Meetings. Recife, Brazil. September 15, 2012.
  35. Lessons Learned and Special Populations from Recent AF Trials: Gaps and what is known. Pfizer Symposium—Anticoagulation in Atrial Fibrillation. Brazilian Society of Cardiology Meetings. Recife, Brazil. September 15, 2012.
  36. Dabigatran is the First Option! Anticoagulation in the Treatment of Atrial Fibrillation. Debate—New Antiplatelet and Anticoagulant Agents for the Treatment of Acute Coronary Syndrome and Atrial Fibrillation. Brazilian Society of Cardiology Meetings. Recife, Brazil. September 15, 2012.
  37. Apixaban in AVERROES and ARISTOTLE. Stroke Prevention in Atrial Fibrillation: Novel Anti-Coagulants and LAA Closure Device. Asia Pacific Heart Rhythm Society Meetings. Taipei, Taiwan. October 4, 2012.
  38. ARISTOTLE: A Major Win over Warfarin in Stroke Prevention in Atrial Fibrillation. Asia Pacific Heart Rhythm Society Meetings. Taipei, Taiwan. October 5, 2012.
  39. SPAF in Western and Asian populations: Similarities, Differences and Clinical Implications. BMS/Pfizer Symposium. Asia Pacific Heart Rhythm Society Meetings. Taipei, Taiwan. October 5, 2012.
  40. Improving Clinical Trials in the US and Japan: Past, Present, and Future. 1st DIA Clinical Operations and Monitoring Workshop. Tokyo, Japan. January 25, 2013.
  41. The Structure and Development of an Academic Research Organization. Chiba University, Chiba, Japan. March 15, 2013.
  42. Apixaban for Stroke Prevention in Patients with Atrial Fibrillation: Lessons from ARISTOTLE and AVERROES. The New Oral Anticoagulants in AF: Meet the Trialists. Japan Circulation Society Meeting 2013. Yokohama, Japan. March 16, 2013.
  43. Apixaban for Stroke Prevention in Patients with Atrial Fibrillation: Lessons from ARISTOTLE and AVERROES. Sponsored Luncheon Seminar. Japan Circulation Society Meeting 2013. Yokohama, Japan. March 16, 2013.
  44. Principles of Phase 1 Studies—New Oral Anticoagulant Study Design and Rationale. SinoAmerica Clinical research Communication—SMART Project. Shanghai, China. May 23, 2013.
  45. Principles of Phase 2 Studies – New Oral Anticoagulant Study Design and Rationale. SinoAmerica Clinical research Communication—SMART Project. Shanghai, China. May 23, 2013.
  46. Is there a Role for Aspirin for Primary Prevention? Brazilian Society of Cardiology and Duke University Symposium. 68th Brazilian Congress of Cardiology. Rio de Janeiro, Brazil. September 29, 2013.
  47. Atrial Fibrillation and Acute Coronary Syndromes: A Challenge in Clinical Practice. VI International Symposium of Thrombosis and Anticoagulation (ISTA) 2013. Porto Alegre, Brazil. October 31, 2013.

48. The Atrial Fibrillation Patient with Coronary Artery Disease. Novel Oral Xa Inhibitors in Cardiology—Today and Tomorrow. EuroPCR 2014. Paris, France. May 23, 2014.
49. Experience from Cardiovascular Trials. Center for Drug Evaluation Regulatory Workshop on Ethnicity and CVD—Consequences for Generalizing Study Results. Beijing, China. June 25, 2014.
50. Implications of Regional Difference in Cardiovascular Studies and the Experience in ARISTOTLE and AVERROES. Interpretation of the China Subgroup Results in Apixaban Stroke Prevention Phase 3 Studies. Beijing, China. June 26, 2014.
51. Overcoming the Dilemma of Stroke versus Bleeding in Non-Valvular Atrial Fibrillation: Can We Optimize Patient Care with Oral Factor XA Inhibition. Refining treatment in atrial fibrillation: the coronary artery disease patient. Satellite Symposium, European Society of Cardiology Congress. Barcelona, Spain. August 31, 2014.
52. The Thrombosis versus Bleeding Risk Dilemma: Practical Considerations with Oral Factor XA Inhibition. Everyday clinical challenges in non-valvular atrial fibrillation and venous thromboembolism: your questions answered—Experts on the Spot. European Society of Cardiology Congress, Satellite Symposium. Barcelona, Spain. September 1, 2014.
53. Innovations in the Care of the Patients with Atrial Fibrillation—ESC and the American Heart Association. What have we learned about novel anticoagulants in AF? European Society of Cardiology Congress. Barcelona, Spain. September 2, 2014.
54. What Have We Learned About Thromboembolism Prophylaxis in Patients with Atrial Fibrillation? Grand Rounds, Gold Coast University Hospital. Southport, Australia. February 5, 2015.
55. What Have We Learned About Thromboembolism Prophylaxis in Patients with Atrial Fibrillation? Grand Rounds, Westmead Hospital. Westmead, Australia. February 6, 2014.
56. The Value of Collaboration in Clinical Research. For Enhancement of Industry-Government Academia Collaboration in Japan. DIA Japan. Tokyo, Japan. November 12, 2015.
57. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, National Heart Institute. Cairo, Egypt. May 9, 2016.
58. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, Erfan Hospital. Jeddah, Saudi Arabia. May 10, 2016. National Heart Institute. Cairo, Egypt. May 9, 2016.
59. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, King Abdulaziz University Hospital. Jeddah, Saudi Arabia. May 10, 2016.
60. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, Holiday Inn Al Qasr Hotel Riyadh. Riyadh, Saudi Arabia. May 10, 2016.
61. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, King Fahd Medical City Hospital. Riyadh, Saudi Arabia. May 11, 2016.
62. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, Security Forces Hospital. Riyadh, Saudi Arabia. May 11, 2016.
63. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, Al Qassimi Hospital. Dubai, United Arab Emirates. May 12, 2016.
64. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation in the Age of NOACs. Grand Rounds, Dusit Thani Hospital. Abu Dhabi, United Arab Emirates. May 12, 2016.

65. Clinical Trials Are the Answer: What's the Question? Pfizer Clinical Trials Learning Series - Understanding Clinical Trials. Dubai, United Arab Emirates. May 13, 2016.
66. Streamlining Clinical Trials: The Practicalities. Program Chair. Society for Clinical Trials Annual Meeting. Montreal, Quebec, Canada. May 17, 2016.
67. Thromboembolism Prophylaxis in Patients with Atrial Fibrillation: The Good News. Anticoagulation: From Mechanisms to Indications and Applications, Symposium. Romanian Society of Cardiology. Sinaia, Romania. September 21, 2016.
68. Apixaban in Fragile Patients. Apixaban from Theory to Clinical Practice, Symposium. Romanian Society of Cardiology. Sinaia, Romania. September 22, 2016.
69. Dual Antiplatelet Therapy in Patients with Atrial Fibrillation. Modern Approach in the Prevention and Treatment of Atrial Fibrillation. Romanian Society of Cardiology. Sinaia, Romania. September 23, 2016.
70. Diabetes and Pfizer Apixaban Dosing. Brazilian Society of Cardiology. Sao Paulo, Brazil. November 4, 2017.
71. Combined Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Bristol Myers Squibb Symposium. Kyoto, Japan. January 22, 2018.
72. Academic Clinical Research Organizations. Chiba University. Chiba, Japan. January 23, 2018.
73. Combined Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Bristol Myers Squibb Symposium. Chiba, Japan. January 23, 2018.
74. Global Cardiovascular Clinical Research. Chiba Junior High School. January 24, 2018.
75. Combined Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. National Cerebral and Cardiovascular Center. Osaka, Japan. January 25, 2018.
76. Dose of Apixaban in Patients with Atrial Fibrillation. Bristol Myers Squibb Symposium. Kyoto, Japan. January 26, 2018.
77. Oral Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease. Bristol Myers Squibb Symposium. Tokyo, Japan. January 27, 2018.
78. Late-breaking Clinical Trials from ACC.18. Pfizer Brazil Masterclass. Recife, Brazil. May 18, 2018.
79. Pitfalls in Stroke Prevention in Atrial Fibrillation. Pfizer Brazil Masterclass. Recife, Brazil. May 19, 2018.
80. BMS Japan Round Table Discussion. ESC 2018. Munich, Germany. August 27, 2018.

**National:**

1. Myocardial Integrity: Importance and Impact of Eptifibatide. GP IIb-IIIa Inhibitors in Acute Coronary Syndromes: Applying Evidence from Clinical Trials to Medical Practice. American College of Cardiology Scientific Session. New Orleans, LA. March 6, 1999.
2. Length of Stay in Acute Myocardial Infarction. ASSENT-II American Investigators Meeting. Washington, DC. October 1, 1999.
3. Time to Treatment in Acute Myocardial Infarction. ASSENT-II American Investigators Meeting. Washington, DC. October 1, 1999.
4. Glycoprotein IIb/IIIa Blockade: Preserving Myocardium in the Non-ST-elevation Acute Coronary Syndromes. GP IIb-IIIa Inhibitors in Acute Coronary Syndromes: Preserving



- Myocardium. American Heart Association, Annual Meetings. Atlanta, GA. November 7, 1999.
5. ASSENT-3 Protocol Overview. ASSENT-3 Investigators Meetings. Toronto, Ontario, Canada. March 31, 2000. Chicago, IL. April 15, 2000.
  6. Acute Coronary Syndromes: Applying the Evidence. Medical Grand Rounds, Aventura Hospital, Aventura, Florida. September 11, 2000.
  7. ASSENT-3. State of the Art Reperfusion in AMI. Boehringer Ingelheim Symposium. Dallas, TX. November 26, 2001.
  8. Anti-Platelet and Anti-Thrombin Therapies in Acute Coronary Syndromes: Hitting the Moving Target. Bellin Health, Annual Cardiology Conference. De Pierre, WI. May 16, 2002.
  9. Meet the Experts—Best Antithrombotic Therapy for Acute Coronary Ischemic Syndromes. American College of Cardiology Scientific Session. New Orleans, LA. March 9, 2004.
  10. Antithrombotic Regimens for Unstable Cardiac Ischemic Syndromes, Emerging Therapies. American College of Cardiology Scientific Session. New Orleans, LA. March 9, 2004.
  11. CRUSADE Quality of Care Teleconference. Conference Call Leader. Prince William Hospital, Manassas, VA. September 22, 2004.
  12. CRUSADE Quality of Care Teleconference. Conference Call Leader. Presbyterian Hospital, Charlotte, NC. October 12, 2004.
  13. CRUSADE Quality of Care Teleconference. Conference Call Leader. University of Arkansas, Little Rock, AK. December 17, 2004.
  14. CRUSADE Quality of Care Teleconference. Conference Call Leader. Crozer-Chester Medical Center, Upland, PA. January 6, 2005.
  15. Meet the Experts—Aspirin and Clopidogrel Resistance in Acute Coronary Syndromes. American College of Cardiology Scientific Session. Orlando, FL. March 9, 2005.
  16. Clinical Research Contracts. Duke Clinical Trials Network (CTN) Best Practices. American Heart Association Scientific Sessions. Dallas, TX. November 12, 2005.
  17. Efficacy and Safety of Edifoligide for the Prevention of Vein Graft Failure in 3014 Patients Undergoing Coronary Artery Bypass Surgery: Primary Results of the PREVENT IV Randomized Clinical Trial. ACCEL Interview, February 2006.
  18. Dosing in Renal Insufficiency. Antithrombotic Approaches in Acute Coronary Syndromes. American College of Cardiology Scientific Session. Atlanta, GA. March 13, 2006.
  19. Direct Factor Xa Inhibitors: The Future of Acute Coronary Syndrome Management. Antithrombotic Therapy in Acute Coronary Syndromes: State of the Art 2007. American College of Cardiology Scientific Session. New Orleans, LA. March 25, 2007.
  20. Implementing Clinical Research in Your Practice. American College of Cardiology Scientific Session. New Orleans, LA. March 27, 2007.
  21. Cardioprotective Effects of Pyridoxal 5'-Phosphate in Patients Undergoing Coronary Artery Bypass Graft Surgery. Novel Cardioprotective Treatment for Coronary Artery Bypass Graft Surgery Symposium. American Association of Thoracic Surgeons Annual Meeting. Washington, DC. May 7, 2007.
  22. The Current State of Antiplatelet Therapy in Acute Coronary Syndromes: The Data and “Real Life.” Platelet Response in Acute Coronary Syndrome CME Symposium. Cleveland, OH. October 18, 2008.

23. Selective Inhibition of Factor Xa in Acute Coronary Syndromes: The APPRAISE and ATLAS Trials. Vascular Biology Working Group Global Chapter Meeting. American Heart Association Scientific Sessions. New Orleans, LA. November 8, 2008.
24. New Anticoagulants in Acute Coronary Syndromes. Anticoagulation Therapy for Cardiovascular Disease: Emerging Treatment Options. Satellite Symposium. American Heart Association Scientific Sessions. New Orleans, LA. November 9, 2008.
25. Challenges of Leveraging Industry, Academic, Government Collaboration: The PREVENT-IV / GENE-MAGIC Story. NIH US Critical Illness and Injury Trials Group Meeting. Bethesda, MD. November 19, 2008.
26. Acute Coronary Syndrome (ACS)—Achieving Effective Secondary Prevention of Thrombosis-Related Events: Factor Xa Inhibition and The Optimal Balance Between Anti-Ischemic Efficacy and Bleeding Risk Reduction. Critical Advances in the Science and Medicine of Thromboembolic Disease: A Year 2009 Panvascular Science-to-Strategy Update (Program Co-Chair). Satellite Symposium. International Society of Thrombosis and Hemostasis Meeting. Boston, MA. July 15, 2009.
27. US Clinical Trials Infrastructure. Japan-US Harmonization by Doing (HBD) West 2009 Meeting—Revisiting the HBD Mission: Past, Present, Future. Washington, DC. July 16, 2009.
28. Phase III Clinical Trial Designs: What are the strengths and weaknesses of various phase III trial designs? Describe and evaluate trial designs that have been used including ‘large simple trials’ and practical clinical trials. National Heart, Lung, and Blood Institute—Workshop: Acute Lung Injury Clinical Research: Beyond Mortality? Bethesda, MD. August 6, 2009.
29. Thrombosis: Describing the Clinical Link between the Coagulation Cascade and Platelet Function (Roundtable Video Conference Chair). State of the Art Anticoagulation in Atrial Fibrillation and Acute Coronary Syndromes (Program Moderator). WebMD. Orlando, FL. November 14, 2009.
30. Classifying Bleeding: Which Scale Should be Used and Why? American College of Cardiology Scientific Session. Atlanta, GA. March 15, 2010.
31. Controlled Anticoagulation During PCI: The Fine Balance of Ischemia and Bleeding. Current and Future Uses of Aptamers in Coronary Syndromes: Looking Beyond the RADAR. Program Chair. Transcatheter Cardiovascular Therapeutics (TCT) Meeting. Washington, DC. September 23, 2010.
32. Japan Harmonization by Doing (HBD) (Working Group 3) Update: US / Japan Clinical Trial Infrastructure. AdvaMed 2010. Washington, DC. October 18, 2010.
33. Applying Risk-Based Monitoring Approaches: An Academic Perspective. Clinical Trials Transformation Initiative (CTTI) Steering Committee Meeting. Washington, DC. November 3, 2011.
34. Early Career: Opening the Door to Successful Careers in Clinical Practice and Clinical Research (Moderator). American Heart Association Scientific Sessions. Orlando, FL. November 12, 2011.
35. Appraising the Role of Oral Anticoagulation in the Secondary Prevention of ACS: Initial Experiences. Evaluating Recent Clinical Trials Data in the Secondary Prevention of ACS. Sponsored Symposium. American College of Cardiology Scientific Session. Chicago, IL. March 24, 2012.

36. Future Requirements: How to Implement the Current Guidelines into Practice. Quality Risk Management in Clinical Drug Development Workshop: Fundamentals and Practical Aspects. Drug Information Association. Philadelphia, PA. December 4, 2012.
37. Strategies for Risk-Based Monitoring, Discussant: A US Academic Perspective. Society for Clinical Trials. Boston, MA. May 20, 2013.
38. Prevention of Stroke in Patients with Non-Valvular Atrial Fibrillation. Progress in the Treatment of Cardiovascular Diseases: 2013—10th Annual Barnabas Health Cardiovascular Symposium. Long Branch New Jersey. September 21, 2013.
39. Novel Targets and Agents for Anticoagulation in NSTEMI-ACS: Pharmacological Strategies to Improve Outcomes in NSTEMI-ACS. American College of Cardiology Meetings. Washington, DC. March 29, 2014.
40. Importance of Clinical Research and the Role of the Academic Investigator. ACC-PPD Investigator Training. American College of Cardiology Heart House. Washington, DC. May 3, 2014.
41. Quality Risk Assessment and Quality by Design—Principles not Jargon. Quality by Design: From Theory to Practice. Drug Information Association Annual Meeting, Preconference Tutorial. San Diego, CA. June 15, 2014.
42. Putting QbD into Practice-Lessons from Real World Example in a Contemporary Cardiovascular Mega-trial. Quality by Design: From Theory to Practice. DIA Annual Meeting, Preconference Tutorial. San Diego, CA. June 15, 2014.
43. Moderator, Samuel A. Levine Young Clinical Investigators Award Finalists. American Heart Association. Orlando, FL. November 7, 2015.
44. State-of-the-art Oral Anticoagulation in Atrial Fibrillation – Findings from ARISTOTLE and the Rationale for AUGUSTUS. Meet the Expert. American Heart Association Meetings. Orlando, FL. November 9, 2015.
45. Pfizer NOACs Meeting – “Are All NOACs the Same?” American College of Cardiology. Chicago, IL. April 2, 2016.
46. Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery with Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial. Late Breaking Clinical Trials: Joint ACC/NEJM. American College of Cardiology. Washington, DC. March 19, 2017.
47. Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery with Cardiopulmonary Bypass: Late Breaking Clinical Trials: Deep Dive II. American College of Cardiology. Washington, DC. March 19, 2017.
48. Combination OAC and Antiplatelet Therapy in Patients with AF and CAD. Meet the Expert at AHA Convention. November 11, 2018.

**Local:**

1. Lidocaine in Acute Myocardial Infarction: Prophylaxis or Poison? Cardiology Grand Rounds, Duke University Medical Center, Durham, NC. June 16, 1997.
2. Myocardial Infarction: A Clinical Research Perspective or When is a Myocardial Infarction a Myocardial Infarction? Cardiology Research Conference. Searle Center, Duke University Medical Center, Durham, NC. June 16, 1999.
3. Acute Coronary Syndromes. Duke Internal Medicine Board Review Course. Durham, NC. June 2001.

4. Research Ethics: Informed Consent in Vulnerable Populations. Bristol-Myers Squibb Research Training Program. Durham, NC. July 9, 2001.
5. Research Ethics: Informed Consent in Vulnerable Populations. Cardiology Grand Rounds, Duke University Medical Center, Durham, NC. August 27, 2001.
6. Transitioning to a Clinical Trials Network—The Society of Thoracic Surgery (STS) Experience. Duke Clinical Research Institute Research Conference, Durham, NC. June 18, 2002.
7. Development of a Direct Factor X Inhibitor: From Bench to Bedside. Cardiology Research Conference. Searle Center, Duke University Medical Center, Durham, NC. June 19, 2002.
8. Post-Operative Cardiovascular Complications. Surgical Residents Conference. Duke University Medical Center, Durham, NC. October 24, 2002.
9. Adjudication of Outcomes by Clinical Endpoint Committees. Pfizer/Duke University Research Training Program. R. David Thomas Executive Center, Durham, NC. March 11, 2003.
10. DSMB Activism: What Can We Learn From The ASSENT-3 Plus Trial. Duke Clinical Research Institute Research Conference, Durham, NC. July 8, 2003.
11. Issues with Endpoints. Electrophysiology Research Conference, Duke University Medical Center, Durham, NC. October 8, 2003.
12. Factor Xa Inhibition in Acute Coronary Syndromes. Cath Lab Conference, Duke University Medical Center, Durham, NC. April 16, 2004.
13. XaNADU-ACS Trial Results. Duke Clinical Research Institute Symposium, Durham, NC. November 30, 2004.
14. The PREVENT IV Trial—Main Results and Lessons for the Duke Clinical Research Institute From A Large Multicenter Trial in Cardiac Surgery. Duke Clinical Research Institute Research Conference, Durham, NC. August 16, 2005.
15. Vein Graft Failure and Clinical Outcomes Following Coronary Artery Bypass Surgery—Lessons from the PREVENT IV trial. Cath Lab Conference, Duke University Medical Center, Durham, NC. February 3, 2006.
16. Improving Vein Graft Patency and Outcomes Following Coronary Artery Bypass Surgery. E2F decoy technology and the PREVENT IV Trial. Cardiovascular Medicine Research Conference. Searle Center, Duke University Medical Center, Durham, NC. February 15, 2006.
17. Duke Clinical Research Site Initiatives—Opportunities, Challenges and State of the Union. Duke Clinical Research Institute Research Conference, Durham, NC. May 9, 2006.
18. Management of Acute Coronary Syndromes in the “Real World”. Daiichi Sankyo Educational Symposium. Duke Clinical Research Institute, Durham, NC. June 27, 2006.
19. Drug-Antidote Pairs as Anticoagulant Systems: The Regado Factor IX Development Program. Duke Clinical Research Institute Research Conference, Durham, NC. January 9, 2007.
20. Management of Acute Coronary Syndromes in the “Real World.” Daiichi Sankyo Educational Symposium. Duke Clinical Research Institute, Durham, NC. February 20, 2007.
21. Duke Cardiovascular Fellows Conference. Clinical Research and Human Subjects. Duke University Medical Center, Durham, NC. February 19, 2007.
22. Weekly Interventional Cardiology (ICC) Conference. State of Site-Based Research at Duke. Duke University Medical Center, Durham, NC. September 24, 2007.
23. TRIUMPH: A Randomized Clinical Trial Experience in Cardiogenic Shock. Duke Clinical Research Institute Research Conference, Durham, NC. January 15, 2008.

24. CT Surgery Clinical Trials Network—Mitral Regurgitation Trials. *Cardiology / Cardiothoracic Surgery Case Management Conference*. Duke University Medical Center, Durham, NC. September 5, 2008.
25. Antithrombotic Strategies in Medically Managed ST-Segment Elevation Myocardial Infarction Patients. *Antithrombotics in ACS: a Virtual Series (theheart.org)*, Durham, NC. October 9, 2008.
26. Long-Term Antithrombotic Therapy after Acute Coronary Syndromes: Walking on a Tightrope. *Duke Cardiology Grand Rounds*, Duke University Medical Center, Durham NC. November 24, 2008.
27. PREVENT-IV: A 2002 to 2009 Update and Scary Observational Findings from a Randomized Trial. *Duke Clinical Research Institute Research Conference*, Durham, NC. June 30, 2009.
28. Developing a New Oral Anticoagulant Post-Acute Coronary Syndromes: Getting from Here to There. *Duke Cardiovascular Symposium*. Durham, NC. May 24, 2010.
29. Latest Developments in the Management of ACS: From Hospital Care to Long-Term Followup. *Duke Clinical Medicine Series*. Asheville, NC. July 22, 2010.
30. American Heart Association Highlights. *Duke Cardiology Grand Rounds*, Duke University Medical Center, Durham NC. November 23, 2010.
31. Clinical Trials Are the Answer: What is the Question? Symposium for Research Administrators, Duke University Medical Center, Durham NC. May 11, 2011.
32. Atrial Fibrillation: Achieving Safer Anticoagulation. *Duke Clinical Medicine Series*, Duke University Medical Center. Durham, NC. May 27, 2011.
33. Clinical Trials: What, When, Where, Who, Why, & How. *Duke Clinical Research Institute Fellows Conference*, Duke University Medical Center, Durham, NC. March 12, 2012.
34. NCBI Emerging Companies Clinical Trials Panel. *Novel Clinical Trial Options – Engaging Academia and Regulators*. Durham, NC. May 1, 2013.
35. Authorship Challenges in Multicenter Clinical Trials. *Duke Clinical Research Institute Fellows Conference*, Duke University Medical Center. Durham, NC. May 6, 2013.
36. The Heart Team in the FFR ERA: Next Steps through the Cardiothoracic Surgery Clinical Trials Network. *Duke Cardiology Grand Rounds*, Durham, NC. October 1, 2013.
37. Working with Industry and Conflicts of Interest. *Duke Clinical Research Institute Fellows Conference*. Duke Medicine, Durham, NC. January 26, 2015.
38. American College of Cardiology 2015—Download at Duke. *Duke Cardiology Grand Rounds*, Durham, NC. April 14, 2015.
39. National Institutes of Health Cardiothoracic Surgical Trials Network (CTSN)—5 Years and the Future. *Duke Surgery Grand Rounds*, Durham, NC. April 15, 2015.
40. Actively Reversible Anticoagulation: From Duke Medicine Bench and Almost to the Bedside. *Duke Clinical Research Institute Research Conference*, Durham, NC. May 26, 2015.
41. Working with Industry and Conflicts of Interest. *Duke Clinical Research Institute Fellows Conference*. Duke Medicine, Durham, NC. February 1, 2016.
42. Update on the Cardiothoracic Surgical Trials Network (CTSN). *Duke Cardiology Grand Rounds*, Durham, NC. August 23, 2016.
43. LEVO-CTS “The Good, The Bad, and The Ugly”. *DCRI Research Forum*. Duke Health, Durham NC, November 28, 2017.

**Areas of research interest:**

Clinical trials methodology  
Clinical research in Japan  
Acute coronary syndromes  
Chronic coronary artery disease  
Cardiovascular surgery  
Atrial fibrillation  
Antithrombotic agents  
Research ethics

**Areas of clinical expertise and activities:**

General non-invasive cardiology, critical care cardiology, valvular heart disease, echocardiography  
Duke Cardiac Care Unit Attending (4 weeks / year)  
Duke Echocardiography Laboratory (one day per week)  
General Cardiology Clinic (one half-day per week)

**Personal information:**

Faculty members' preferred familiar name: John Alexander  
Local home address: 202 Pitch Pine Lane  
Chapel Hill, NC 27514  
Local home phone: (919) 932-6053 Marital status: Married with  
children Name of spouse: Karen P. Alexander, M.D.  
Name of children: Emily P. Alexander (September 15, 1997)  
Benjamin H. Alexander (June 20, 2001)  
Megan E. Alexander (May 10, 2006)